Role of SOCS proteins in FLT3-ITD and BCR/ABL mediated leukemogenesis by Reddy, N. G. Pavan Kumar
Pavan Kumar Reddy, N.G
L
a
c
k
 
o
f
 
c
y
t
o
k
i
n
e
 
c
o
n
t
r
o
l
Role of SOCS proteins in FLT3-ITD and BCR/ABL mediated 
leukemogenesis
2010
SOCS1 cooperates with FLT3-ITD by promoting the escape 
from external cytokine control 
 
Role of SOCS proteins in FLT3-ITD and BCR/ABL 
mediated leukemogenesis 
 
 
 
Dissertation to obtain the Degree of Doctor of Philosophy  
at the Faculty of Natural Sciences 
 
 
 
Submitted to the Faculty of Biochemistry, Chemistry 
 and Pharmacy of the Goethe University 
in Frankfurt am Main 
 
 
 
 
by 
Pavan Kumar Reddy, N.G. 
From Vepakunta, India. 
   
Frankfurt am Main, 2010 
 
 
 
 
  (D30)    
 
Submitted to the Faculty of Biochemistry, Chemistry and Pharmacy of 
the Goethe University in Frankfurt am Main 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dean: Prof. Dr. Dieter Steinhilber 
Examiners:  
1.  Prof. Dr. Rolf Marschalek 
2.  Prof. Dr. Hubert Serve 
 
Date: 24-11-2010    Table of Contents 
 
 
  iii 
Table of Contents 
Table of Contents ................................................................................ iii 
Summary  ............................................................................................. vii 
Zusammenfassung  .............................................................................. ix 
1  Introduction  ...................................................................................... 1 
1.1  Hematopoiesis ............................................................................................. 1 
1.2  Leukemia ...................................................................................................... 2 
1.2.1  Acute myeloid leukemia (AML) ..........................................................................  3 
1.2.2  Acute lymphoblastic leukemia (ALL) ..................................................................  3 
1.3  Two hit model of leukemogenesis  .............................................................. 4 
1.4  Oncogenic tyrosine kinases implicated in leukemia ................................ 5 
1.5  FLT3 (FMS-like tyrosine kinase 3) receptor ............................................... 5 
1.5.1  Expression and functions of FLT3 receptor in normal hematopoiesis  .................  6 
1.5.2  FLT3 ligand  ........................................................................................................  7 
1.5.3  FLT3 mutations in leukemia ...............................................................................  7 
1.5.4  Activation of FLT3-WT and FLT3-ITD receptors  .................................................  8 
1.5.5  Signaling and biological differences of FLT3-WT and FLT3-ITD ........................  9 
1.5.6  Mouse models for FLT3-ITD ............................................................................  10 
1.6  The Philadelphia Chromosome (BCR/ABL) ............................................. 10 
1.6.1  BCR/ABL signaling ..........................................................................................  11 
1.6.2  Mouse models for BCR/ABL ............................................................................  11 
1.7  Physiological cytokine/JAK/STAT signaling pathway ............................ 12 
1.8  Oncogenic JAK/STAT pathway  ................................................................. 14 
1.9  SOCS proteins  ............................................................................................ 15 
1.9.1  Expression of SOCS proteins ..........................................................................  16 
1.9.2  CIS ..................................................................................................................  16 
1.9.3  SOCS1 ............................................................................................................  17 
1.9.4  SOCS2 ............................................................................................................  19 
1.9.5  SOCS3 ............................................................................................................  19 
1.9.6  SOCS4-7 .........................................................................................................  19 
1.10 SOCS proteins in cancer ........................................................................... 20 
2  Objectives ...................................................................................... 21 
2.1  Hypothesis  .................................................................................................. 21 
2.2  Specific objectives  ..................................................................................... 21     Table of Contents 
 
  iv 
3  Materials and Methods .................................................................. 22 
3.1  Materials ..................................................................................................... 22 
3.1.1  Instruments and apparatus ..............................................................................  22 
3.1.2  Kits ..................................................................................................................  22 
3.1.3  Chemokines and cytokines ..............................................................................  23 
3.1.4  Enzymes  ..........................................................................................................  23 
3.1.5  Primary antibodies used for western blotting  ....................................................  23 
3.1.6  Secondary antibodies ......................................................................................  24 
3.1.7  FACS antibodies  ..............................................................................................  24 
3.1.8  Cell culture media and reagents ......................................................................  25 
3.1.9  Bacteria ...........................................................................................................  26 
3.1.10  Cell lines ..........................................................................................................  26 
3.1.11  Long-term cultured primary lymphoblastic leukemia cells from  patients .......... 27 
3.1.12  Mice  .................................................................................................................  27 
3.1.13  Patient samples ...............................................................................................  27 
3.2  Methods ...................................................................................................... 28 
3.2.1  Cell culture  .......................................................................................................  28 
3.2.2  RNA preparation, quantitative PCR (polymerase chain reaction) ..................... 28 
3.2.3  Plasmids and Cloning ......................................................................................  31 
3.2.4  Generation of stable 32D and Ba/F3 cell lines .................................................  32 
3.2.5  3[H]-thymidine incorporation assay ..................................................................  33 
3.2.6  Competitive proliferation assay by FACS .........................................................  33 
3.2.7  Stimulation of cells ...........................................................................................  33 
3.2.8  Western blotting  ...............................................................................................  33 
3.2.9  Flow cytometry................................................................................................. 34 
3.2.10  Primary murine bone marrow  ...........................................................................  34 
3.2.11  Retroviral supernatants and transduction of murine bone marrow.................... 34 
3.2.12  Colony assay of murine bone marrow cells  ......................................................  34 
3.2.13  Transplantation of murine bone marrow and assessment of mice  .................... 35 
3.2.14  Cytospin preparations and Wright Giemsa staining  ..........................................  35 
3.2.15  Histology and Microscopy ................................................................................  35 
3.2.16  Software and Statistics ....................................................................................  36 
4  Results ........................................................................................... 37 
4.1  Role of SOCS1 in FLT3-ITD mediated leukemogenesis  .......................... 37 
4.2  Retroviral expression of FLT3-ITD in 32D, Ba/F3 and murine bone 
marrow induced SOCS gene expression .................................................. 37     Table of Contents 
 
 
  v 
4.2.1  Ectopic expression FLT3-ITD induced CIS, SOCS1-2 expression in 
hematopoietic cell lines ...............................................................................................  37 
4.2.2  SOCS1 expression was highly induced by FLT3-ITD in murine bone marrow  .. 38 
4.3  Kinase dependent expression of SOCS genes in FLT3-ITD
+ AML 
derived cell lines ......................................................................................... 39 
4.4  SOCS1 is highly expressed in FLT3-ITD
+ AML patient bone marrow  .... 40 
4.5  Role of SOCS1 in FLT3-ITD mediated transformation in vitro ............... 41 
4.5.1  SOCS1 co-expression with FLT3-ITD ..............................................................  41 
4.5.2  SOCS1 co-expression did not affect FLT3-ITD mediated signaling pathways .. 41 
4.5.3  SOCS1 co-expression did not affect FLT3-ITD mediated proliferation but 
abrogated IL-3 mediated proliferation and protected from Interferon mediated 
growth inhibition ...............................................................................................  42 
4.5.4  Interferon alpha and Interferon gamma induced STAT1 activation is diminished 
by FLT3-ITD  .....................................................................................................  44 
4.5.5  SOCS1 co-expression with FLT3-ITD protected primary bone marrow from 
Interferon gamma.............................................................................................  45 
4.6  Role of SOCS1 expression in FLT3-ITD induced leukemogenesis in  
vivo ............................................................................................................... 48 
4.6.1  SOCS1 co-expression enhanced FLT3-ITD bone marrow engraftment and 
proliferation ......................................................................................................  48 
4.6.2  SOCS1 co-expression accelerated the onset of FLT3-ITD induced 
myeloproliferative disease and acute lymphoblastic leukemia  ..........................  50 
4.6.3  Spleen, liver and bone marrow infiltration in FLT3-ITD or SOCS1-T2A-FLT3-
ITD transplanted mice ......................................................................................  52 
4.6.4  SOCS1 co-operates with MPD development ...................................................  55 
4.6.5  Model for SOCS1 co-operation with FLT3-ITD  .................................................  55 
4.7  Role of SOCS proteins in BCR/ABL mediated leukemogenesis ............ 57 
4.8  SOCS gene expression in patient derived ALL cells .............................. 57 
4.8.1  CIS, SOCS2, SOCS3 were highly expressed in BCR/ABL positive, long-term 
cultures of primary acute lymphoblastic leukemia patient samples  ................... 57 
4.8.2  CIS, SOCS2 and SOCS3 expression is Abl kinase dependent in long-term 
cultures of primary acute lymphoblastic leukemia patient samples  ................... 58 
4.9  Kinase dependent expression of CIS, SOCS1 and SOCS3 in K-562 cell 
line ................................................................................................................ 58 
4.10 Ectopic expression of BCR/ABL in murine bone marrow induced SOCS 
gene expression  .......................................................................................... 59 
4.11 SOCS1 did not affect BCR/ABL mediated proliferation, while  
abrogating IL-3 mediated proliferation  ...................................................... 60 
5  Discussion ..................................................................................... 62 
6  References ..................................................................................... 68     Table of Contents 
 
  vi 
7  Eidesstattliche erklärung .............................................................. 84 
Abbreviations ..................................................................................... 85 
Curriculum Vitae  ................................................................................. 88 
Acknowledgements  ............................................................................ 92 
     Summary 
 
 
  vii 
Summary 
Acute myeloid/lymphoid leukemia is a fatal hematological malignancy characterized 
by accumulation of nonfunctional, immature blasts, which interferes with the 
production of normal blood cells. Activating mutations of receptor tyrosine kinases 
are common genetic lesions in leukemia.  FLT3-ITD is a frequent activating 
mutation found in AML patients, leading to uncontrolled proliferation of leukemic 
blasts. FLT3-ITD directly activates STAT5, leading to the induction of STAT5 target 
gene expression like PIM kinases and SOCS genes. STAT5 and PIM kinases have 
been shown to play a crucial role in the FLT3-ITD mediated transformation. On the 
other hand, the role of SOCS proteins in FLT3-ITD mediated transformation has not 
been studied to date. SOCS proteins are part of a negative feedback mechanism 
that controls Jak kinases downstream of cytokine receptors. One of the SOCS 
family members, SOCS1 has been reported to suppress oncogenecity of several 
activating kinases implicated in hematologic malignancies. In this thesis the role of 
these SOCS proteins in FLT3-ITD mediated transformation (in vitro) and 
leukemogenesis (in vivo) is systematically explored.  
Expression of FLT3-ITD in cell lines of myeloid (32D) and lymphoid (Ba/F3) origin, 
led to CIS, SOCS1 and SOCS2 expression. FLT3-ITD expression in primary murine 
bone marrow stem/progenitor cells led to a 59 fold induction of SOCS1 expression. 
Furthermore, FLT3-ITD positive AML cell lines (MV4-11, MOLM-13) show kinase 
dependent CIS, SOCS1, and SOCS3 expression. Importantly SOCS1 is highly 
expressed in AML patients with FLT3-ITD compared to healthy individuals. SOCS1 
protein was expressed in FLT3-ITD transduced murine bone marrow stem cells and 
SOCS1 expression was abolished with kinase inhibition in MOLM-13 cell line. In 
conclusion, SOCS1 was highly regulated by FLT3-ITD in myeloid, lymphoid cell 
lines, in bone marrow stem/progenitors and in AML patient samples. 
SOCS1 co-expression did not affect FLT3-ITD mediated signaling and proliferation, 
but abolished IL-3 mediated proliferation and protected 32D cells from interferon-α 
and interferon-γ mediated growth inhibition. FLT3-ITD expressing 32D cells showed 
diminished STAT1 activation in response to interferons (α and γ). Alone, SOCS1 
strongly inhibited cytokine induced colony formation of bone marrow stem and 
progenitors, but not FLT3-ITD induced colony formation. Most importantly, in the     Summary 
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presence of growth inhibitory interferon-γ, SOCS1 co-expression with FLT3-ITD led 
to increased colony formation compared to FLT3-ITD alone. Taken together, FLT3-
ITD induced and exogenously expressed  SOCS1, shielded cells from external 
cytokines, signals, while not affecting FLT3-ITD induced proliferation/signaling. 
In further experiments the in vivo effects of SOCS1 were studied in a bone marrow 
transplantation model. SOCS1 bone marrow transplants were unable to 
engraft/proliferate in mice. FLT3-ITD was shown to induce a myeloproliferative 
disease. Both control (empty vector), SOCS1 transplanted mice were normal and 
did not show any disease phenotype. FLT3-ITD alone and SOCS1 co-expressing 
FLT3-ITD developed either myeloproliferative disease or acute lymphoblastic 
leukemia with equal distribution. SOCS1 co-expression with FLT3-ITD led to a 
decreased latency. Mice transplanted with FLT3-ITD alone and SOCS1 co-
expressing FLT3-ITD displayed enlarged spleens, liver and hypercellular bone 
marrow indicating infiltration of leukemic cells. Mice were also anemic and showed 
decreased platelet counts. Importantly SOCS1 co-expression particularly shortened 
the latency of myeloproliferative disease but not of acute lymphoblastic leukemia. In 
summary, in the context of FLT3-ITD, SOCS1 acts as a ‘conditional oncogene’ and 
cooperates with FLT3-ITD in the development of myeloproliferative disease.  With 
these data we propose the following model: FLT3-ITD induces SOCS gene 
expression, which shields cells against proliferation and differentiation signals from 
cytokines, while not affecting FLT3-ITD mediated proliferative signals. This leaves 
cells under the dictate of FLT3-ITD thereby contributing to leukemogenesis.  
Similar to FLT3-ITD, BCR/ABL (P190) (an oncogenic fusion kinase often found in 
acute lymphoblastic leukemia) induces SOCS gene expression in K562 and long-
term cultured cells from patients with acute lymphoblastic leukemia. SOCS1 co-
expression does not affect BCR/ABL mediated proliferation while abrogating IL-3 
mediated proliferation. These findings suggest that SOCS proteins may play a 
general co-operative role in the context of oncogenes which aberrantly activate 
STAT3/5 independently of JAK kinases. This study reveals a novel molecular 
mechanism of FLT3-ITD mediated leukemogenesis and suggests SOCS genes as 
potential therapeutic targets.     Zusammenfassung 
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Zusammenfassung 
Akute Leukämien sind unbehandelt tödlich verlaufende, hämatologische 
Erkrankungen, bei denen es zu einer Anreicherung unreifer und funktionsloser 
Blasten im Knochenmark kommt, was wiederum mit der gesunden Hämatopoese 
interferiert. Ursache dieser Leukämien sind chomosomale Translokationen oder 
Funtionsgewinn- bzw. Funktionsverlustmutationen. Die Mehrheit dieser Mutationen 
tritt in Genen auf, die Proliferation und/oder Differenzierung regulieren. Im Rahmen 
dieser Dissertation wurde die Rolle einer dieser Mutationen der 
Rezeptortyrosinkinase FLT3 in der Leukämogenese bearbeitet, genannt FLT3-ITD 
(interne Tandemduplikation). FLT3 wird in frühen hämatopoetischen Stamm- und 
Progenitorzellen exprimiert und spielt eine wichtige Rolle für das Überleben und die 
Proliferation lymphatischer und myeloischer Linien. Die Bindung des FLT3 
Liganden an den Wildtyp-FLT3 Rezeptor führt zur dessen Dimerisierung und 
Aktivierung, wobei diese Aktivierung wiederum unterschiedliche Signalwege wie 
z.B. PI3K/Akt und Erk aktiviert. FLT3-ITD ist eine  aktivierende Mutation der FLT3 
Rezeptortyrosinkinase, die bei etwa 25 % der AML-Patienten gefunden wird und 
zur unkontrollierten Proliferation leukämischer Blasten führt. Diese Mutation führt zu 
einer Ligand-unabhängigen, konstitutiv aktiven Form des Rezeptors, so dass die 
nachfolgenden Signalwege (PI3K/Akt, Erk und STAT5) permanent angeschaltet 
sind. Ein Genexpressionsprofil in FLT3-ITD exprimierenden 32D Zellen im 
Vergleich zu Ligand aktivierten Wildtyp-FLT3 exprimierenden Zellen zeigt eine 
erhöhte Expression von STAT5 Zielgenen wie PIM Kinasen und SOCS Proteinen. 
Interessanterweise aktiviert FLT3-ITD STAT5 dabei unabhängig von Jak und Src 
Kinasen und verleiht IL-3 abhängigen Zelllinien wie 32D und Ba/F3 ein Faktor 
unabhängiges Wachstum. Weiterhin verursacht eine FLT3-ITD Expression im 
Gegensatz zum Wildtyp-FLT3 in Maustransplantationsexperimenten  eine  
myeloproliferative Erkrankung.  
Vergleichbar mit FLT3-ITD ist BCR/ABL auch ein onkogenes Fusionsprotein, das 
durch eine Translokation zwischen den Chromosomen 9 und 22, bezeichnet als  
t(9;22), zustande kommt. Das BCR/ABL Protein wird in ca. 90 % aller chronischen 
myeloischen Leukämien (CML) und in 10-20 % aller akuten lymphatischen 
Leukämien (ALL) gefunden. Wie FLT3-ITD verleiht auch BCR/ABL 32D und Ba/F3     Zusammenfassung 
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Zellen ein IL-3 unabhängiges Wachstum. Außerdem führt es zu einer konstitutiven 
Aktivierung der PI3K/AKT, Ras/MAPK und STAT5 Signalwege. Die BCR/ABL 
vermittelte Aktivierung von STAT5 erfolgt hierbei entweder durch direkte 
Phosphorylierung oder über die Src Kinase HCK. Im 
Knochenmarktransplantationsmodell induziert BCR/ABL  eine myeloproliferative 
Erkrankung, die einer CML ähnelt. 
Die Produktion hämatopoetischer Zellen unterliegt einer strengen Kontrolle durch 
hämatopoetische Zytokine. Die Zytokinrezeptoren besitzen keine intrinsische 
Kinaseaktivität. Die Signalweiterleitung erfolgt hier über Jak Kinasen.  Auf diese 
Weise kontrollieren Zytokinrezeptoren wichtige Prozesse des Immunsystems und 
der Blutzellhomöostase. SOCS Proteine sind Teil eines negativen 
Rückkopplungsmechanismus, der die Aktivierung von STAT Proteinen durch 
Zytokinrezeptoren kontrolliert. SOCS Proteine binden an Jak Kinasen und 
inhibieren deren Kinaseaktivität über verschiedene Mechanismen, was zur 
Termination der Zytokinsignale führt. Von einem Mitglied der SOCS Familie, 
SOCS1, ist bekannt, dass es durch die Hemmung einiger aktivierender Kinasen bei 
hämatologischen Erkrankungen tumorsupressive Eigenschaften hat. Die Rolle der 
SOCS Proteine in der FLT3-ITD vermittelten Transformation ist bis heute nicht 
hinreichend analysiert. Insbesondere ist unklar wie transformierte Zellen der 
strengen Kontrolle des Zytokinnetzwerks entgehen können, das normalerweise die 
korrekte Funktion hämatopoetischer Zellen garantiert. 
In der vorliegenden Arbeit wurde die Rolle von SOCS Proteinen in der FLT3-ITD 
vermittelten Transformation (in vitro) und Leukämieentstehung (in vivo) 
systematisch untersucht. Weiterhin wurde die SOCS Genexpression und die 
Folgen der BCR/ABL vermittelten Transformation analysiert. 
Schlussfolgerung 1: FLT3-ITD induziert die Expression von SOCS Genen in 
Zelllinien und murinen Knochenmarkzellen; SOCS1 ist in Patienten mit FLT3-
ITD
 induziert. 
Zunächst wurden bestehende microarray Daten durch quantitative real time PCR 
validiert. Die Expression von FLT3-ITD in myeloischen (32D) und lymphatischen 
(Ba/F3) Zelllinien  induziert die Expression von CIS, SOCS1 und SOCS2. In 
primärem murinen Knochenmarksstamm-/progenitorzellen führt die Expression von     Zusammenfassung 
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FLT3-ITD zu einem sehr starken Anstieg der SOCS1 Expression (59-fach). Zudem 
zeigen Zelllinien, die von FLT3-ITD positiven AML-Patienten gewonnen wurden 
(MV4-11, MOLM-13), eine Kinase abhängige CIS, SOCS1 und SOCS3 Expression. 
Interessanterweise wird außerdem SOCS1 im Knochenmark von AML-Patienten 
mit FLT3-ITD Mutationen im Vergleich zu Kontrollen von gesunden Spender stark 
überexprimiert. Das SOCS1 Protein wird ferner in FLT3-ITD  transduziertem  
murinen Knochenmark exprimiert und die Expression geht in MOLM-13 Zellen nach 
Behandlung mit Kinaseinhibitoren verloren. Zusammenfassend wird die Expression 
von SOCS1 in hohem Maße durch FLT3-ITD in myeloischen und lymphatischen 
Zelllinien sowie in hämatopoetischen  Stamm-  und Progenitorzellen und AML-
Patienten hochreguliert. 
Schlussfolgerung 2: Die SOCS1 Expression verhindert Zytokinrezeptor 
vermittelte Effekte aber nicht die FLT3-ITD induzierte Signalgebung und 
Proliferation. 
Aufgrund der hohen SOCS1 Induktion durch FLT3-ITD im primären murinen 
Knochenmark und in Patientenproben wurde dessen Rolle in der FLT3-ITD 
vermittelten Transformation untersucht. Die Koexpression von SOCS1 
beeinträchtigt nicht die durch FLT3-ITD induzierten Signalwege (MAPK/ERK, 
PI3K/AKT und STAT5) oder die Proliferation, jedoch unterbindet es die IL-3 
vermittelte Proliferation und schützt 32D Zellen vor der Wachstumshemmung durch 
Interferon  α  und  γ. So zeigten FLT3-ITD exprimierende 32D Zellen eine 
verminderte STAT1-Aktivierung durch Interferon α  und  γ. In einem kompetitiven 
Proliferationsassay wirkte die SOCS1 Expression alleine wachtumsinhibierend, 
koexprimiert mit FLT3-ITD trat allerdings der gegenteilige Effekt auf. Im murinen 
Knochenmark führte SOCS1 zu einer starken Hemmung der Zytokin  induzierten 
Kolonienbildung hämatopoetischer Stamm- und Progenitorzellen, jedoch nicht der 
FLT3-ITD induzierten Kolonienbildung, was auf eine SOCS1 Resistenz von FLT3-
ITD hindeutet. Interessanterweise führte SOCS1 in Anwesenheit des 
wachstumhemmenden Interferons γ  zu einer Verstärkung der  FLT3-ITD 
induzierten Kolonienbildung.  Zusammenfassend führt die FLT3-ITD induzierte oder 
exogene SOCS1 Expression zu einer Abschirmung der Zellen von exogenen 
Zytokinsignalen, während die FLT3-ITD vermittelten, zellulären Effekte 
unbeeinflusst bleiben.     Zusammenfassung 
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Schlussfolgerung 3: SOCS1 Expression verstärkt die myeloproliferative 
Erkrankung, die durch FLT3-ITD  induziert wird: SOCS1 als „konditionales 
Onkogen“. 
Für FLT3-ITD wurde bereits die Entstehung einer myeloproliferativen Erkrankung 
und   einer akuten lymphozytischen B-  und T-Zellleukämie im murinen 
Knochenmark gezeigt. Im transgenen Mausmodell löst FLT3-ITD entweder eine 
myeloproliferative oder eine  lymphatische Erkrankung aus.  
In dieser Arbeit wurde die Rolle von SOCS1 in der FLT3-ITD vermittelten Leukämie 
im Knochmarktransplantationsmodell in vivo  untersucht. Die Übertragung der in 
vitro  gefundenen Effekte von SOCS1 auf FLT3-ITD in das Mausmodell in vivo 
zeigte, dass es bei der Transplantation von SOCS1 exprimierendem Knochenmark 
nicht zu einem Anwachsen oder zur Proliferation in der Maus kommt, was einen 
kompetitiven Wachstumsnachteil dieser Zellen demonstriert. SOCS1 und FLT3-ITD 
koexprimierende Transplantate zeigten jedoch eine höhere Proliferationsrate in 
vivo  als ausschließlich Flt3-ITD exprimierende Zellen. Sowohl Kontroll-  als auch 
SOCS1 transplantierte Mäuse waren unauffällig und ohne erkennbaren Phänotyp. 
Mäuse mit Flt3-ITD transduzierten oder FLT3-ITD und SOCS1 koexprimierenden 
Transplantaten entwickelten zu gleichen Teilen entweder eine myeloproliferative 
Erkrankung oder eine akute lymphatische Leukämie. Die Koexpression von SOCS1 
mit FLT3-ITD führte zu einer verkürzten Latenzzeit. Mäuse mit FLT3-ITD 
transduzierten Transplantaten (mit oder ohne SOCS1) zeigten vergrößerte Milzen 
und Lebern sowie ein hyperzelluläres Knochenmark als Anhaltspunkt  für  eine 
Infiltration mit leukämischen Blasten. Ferner waren die Mäuse anämisch und hatte 
eine verminderte Thrombozytenzahl. Interessanterweise verkürzte die 
Koexpression von SOCS1  die Latenzzeit für die myeloproliferative Erkrankung, 
aber nicht für die akute lymphatische Leukämie. Zusammenfassend wirkt SOCS1 
im Zusammenhang mit FLT3-ITD als konditionales Onkogen und kooperiert mit 
FLT3-ITD bei der Entstehung der myeloproliferativen Erkrankung.   
Schlußfolgerung 4: SOCS Gene werden durch BCR/ABL  induziert. SOCS1 
Expression beeinflusst nicht die BCR/ABL vermittelte Transformation. 
Eine Aktivierung von STAT5 wurde im Zusammenhang mit mehreren 
hämatologischen, malignen Erkrankungen, die  durch onkogene Kinasen ausgelöst     Zusammenfassung 
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wurden, beobachtet. Da BCR/ABL  STAT5 stark aktiviert, wurde die SOCS 
Genexpression in BCR/ABL  positiven Zelllinien und im Knochenmark mittels 
quantitativer PCR analysiert. Im Vergleich zu BCR/ABL  negativen ALL Zellen 
wurde in BCR/ABL positiven, primären ALL Zellen eine Induktion von CIS, SOCS2 
und SOCS3 beobachtet. Die Inhibition der ABL Kinaseaktivität in BCR/ABL 
positiven, primären ALL Zellen durch Zugabe von Imatinib führte zu einer 
Verminderung der SOCS Expression, was  eine Kinase abhängige Expression 
dieser Proteine demonstriert. Ebenso konnte auch in der BCR/ABL  positiven 
Zelllinie K562 durch die Inhibition der ABL Kinaseaktivität mittels Imatinib eine 
Reduktion von CIS, SOCS1 und SOCS3 demonstriert werden. Die Expression von 
BCR/ABL im primären murinen Knochenmark induzierte eine hohe Expression von 
CIS, SOCS1 und SOCS3. Die Koexpression von SOCS1 beeinflusste nicht die 
BCR/ABL vermittelte Proliferation, während aber die IL-3 vermittelte Proliferation 
unterdrückt wurde, was auf eine SOCS1 Resistenz von BCR/ABL deutet. 
Mit diesen Ergebnissen schlagen wir ein Modell vor, bei dem FLT3-ITD die 
Expression von SOCS Genen induziert, welche wiederum die Zelle von pro- oder 
antiproliferativen sowie Differenzierungssignalen exogener Zytokine abschirmen, 
ohne die FLT3-ITD vermittelten Signale zu beeinflussen. So verbleibt die Zelle 
einzig unter der Kontrolle von FLT3-ITD, was zur Leukämieentstehung beiträgt. 
Dieses Model erklärt das ‚SOCS Paradoxon’, in dem die scheinbar gegensätzlichen 
Ergebnisse der erhöhten Expression der Tumorsupressorproteine der SOCS 
Familie im Kontext mit onkogenen Kinasen wie FLT3-ITD stehen. 
Die vorliegende Untersuchung zeigt einen neuen molekularen Mechanismus der 
FLT3-ITD vermittelten Leukämieentstehung. Mechanistisch setzen SOCS Proteine 
die externe  Kontrolle durch Zytokine außer Kraft und wirken so positiv in der 
Leukämogenese. Dies deutet auf eine Rolle von SOCS Proteinen als mögliche 
therapeutische Zielstrukturen hin. Diese Beobachtungen legen nahe, dass SOCS 
Proteine generell mit Onkogenen kooperieren, die eine aberrante Aktivierung von 
STAT3/5 unabhängig von JAK Kinasen, induzieren. 
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1  Introduction 
1.1  Hematopoiesis 
Hematopoiesis is the continuous process through  which all blood cell types are 
produced from the hematopoietic stem cell (HSC). HSCs emerge from the primitive 
ventral mesenchyme  during early development. In the fetus, the sites of 
hematopoiesis include the yolk sac and the liver, whereas in the adult, the primary 
site of hematopoiesis is the bone marrow (Orkin and Zon, 2008; Weissman, 2000; 
Weissman et al., 2001). 
  
 
Figure 1: Hematopoietic-progenitor cell lineages and the hematopoietic hierarchy. HSCs can 
be divided into LT-HSCs, highly self-renewing cells that reconstitute an animal for its entire life span, 
or ST-HSCs, which reconstitute the animal for a limited period. ST-HSCs differentiate into MPPs, 
which do not or briefly self-renew, and have the ability to differentiate into oligolineage-restricted 
progenitors that ultimately give rise to differentiated progeny through functionally irreversible 
maturation (Passegue et al., 2003). 
 
The blood consists of various types of cells which are divided into myeloid and the 
lymphoid cells.  The myelo-erythroid lineage includes erythrocytes, which transport 
oxygen and carbon dioxide to and from the lungs to tissues, and platelets, which 
are important for blood coagulation and wound healing. Monocytes/granulocytes, 
migrate into the tissues and are involved in inflammation and phagocytosis. The     Introduction 
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lymphoid cells include the B-lymphocytes, which provide immunity by the 
production of specific antibodies, and the T-lymphocytes, which eliminate cells that 
have foreign molecules on their surface. In a healthy individual the various types of 
blood cells are maintained at constant proportions throughout life. 
HSCs are functionally defined by their unique ability to self-renew and to 
differentiate to form all mature blood cell types.   Based on how long they can 
repopulate lethally irradiated mice, HSCs are divided into either long-term HSC (LT-
HSC) or short-term HSC (ST-HSC) (Morrison and Weissman, 1994). These HSCs 
subsequently  form  multi-potent progenitors (MPPs) that generate committed 
progenitors of different lineages, the common myeloid progenitor (CMP) for the 
myelo-erythroid lineage and the common lymphoid progenitor (CLP) for the 
lymphoid lineage. The CMP in turn gives rise to the granulocyte-macrophage 
progenitor (GMP) and the megakaryocyte-erythrocyte progenitors (MEP).  These 
progenitors will give rise to all mature blood cells. Thus the hematopoietic hierarchy 
is composed of stem cells,  committed progenitors and their progeny and mature 
blood cells of all lineages (Figure 1) (Orkin and Zon, 2008; Weissman, 2000; 
Weissman et al., 2001). 
1.2  Leukemia 
Leukemia is the malignant growth of the progenitor cells from which mature blood 
cells develop. The underlying process of development of leukemia is called 
leukemogenesis. Leukemias are often broadly classified as ‘acute’ and ‘chronic’, 
based on the duration for the disease to manifest and progress. Acute leukemias 
often progress very rapid and can be fatal within few weeks to months. Chronic 
leukemias progress gradually over a period of years of time. Leukemias are 
classified depending on the type of cells that are abnormally growing: for example 
myeloid or lymphoid leukemias.  
Leukemia are classified based upon whether the leukemia is acute versus chronic 
and myeloid versus lymphoid that is:  
•  Acute myeloid leukemia (AML)  
•  Chronic myeloid leukemia (CML)  
•  Acute lymphoblastic leukemia (ALL)      Introduction 
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•  Chronic lymphoblastic leukemia (CLL)  
As the present study mainly deals with  the acute leukemias, these types are 
explained in more detail. 
1.2.1  Acute myeloid leukemia (AML) 
AML is characterized by the malignant transformation of myeloid stem/progenitor 
cells in the bone marrow, which are incapable of normal differentiation and 
maturation, resulting in ‘blast’ cells. As a consequence, production of normal 
marrow cells is perturbed, leading to a deficiency of red cells, blood-clotting 
platelets and normal infection-fighting white cells. Since normal hematopoiesis is 
organized hierarchically, AML may arise in a stem cell capable of differentiating into 
cells of erythroid, granulocytic, monocytic and megakaryocytic lineages. The FAB 
(French-American-British) classification system divides AML into 9 subtypes based 
on maturation-stage, the type of cell from which the leukemia developed. 
M0: Minimally differentiated  M4: Myelomonocytic leukemia 
M1: Myeloblastic leukemia 
without maturation 
M4 variant:  increase in marrow 
eosinophils 
M2: Myeloblastic leukemia with 
maturation  M5: Monocytic leukemia 
M3: Hypergranular promyelocytic 
leukemia  M6: Erythroleukemia 
M3v: Microgranular 
promyelocytic leukemia 
M7: Megakaryoblastic leukemia 
 
More recently the FAB classification has been replaced by the WHO (World Health 
Organization) system based on the cytogenetic, chromosomal abnormalities (Harris 
et al., 1999; Vardiman et al., 2009). The WHO also set the diagnosis of AML to be 
at least 20% of the cells identified in the blood or bone marrow as blasts of myeloid 
origin. Myeloproliferative disease  is characterized by increased accumulation of 
mature myeloid cells in the peripheral blood and bone marrow. 
1.2.2  Acute lymphoblastic leukemia (ALL) 
ALL is characterized by abnormalities of the lymphoid cell precursors leading to 
excessive accumulation of leukemic lymphoblasts (either B or T cells) in the bone 
marrow and other organs, in particular the spleen and liver. ALL most commonly     Introduction 
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affects children, particularly those between 3 and 10 years of age. It accounts for 
about 85% of all childhood leukemias. It also affects older adults. FAB classification 
of ALL has three subtypes. The FAB classification has been revised and replaced 
by WHO (Harris et al., 1999; Vardiman et al., 2009).  
L1: Small homogeneous, high nuclear: cytoplasmic ratio, small nucleoli 
L2: Larger, pleomorphic, low nuclear: cytoplasmic ratio, prominent nucleoli 
L3:  Larger, vacuolated basophilic cytoplasm, large vesicular nucleus, large 
nucleoli; resemble Burkitt’s lymphoma cells 
1.3  Two hit model of leukemogenesis 
Development of leukemia is multi-step process. Majority of the mutations found in 
AML patients, when expressed in mouse develops a pre-leukemic condition. 
Studies in mice using genetic alterations found in AML patients have shown that a 
minimum of two genetic alterations (genetic hits) is required for pre-leukemic 
myeloproliferation to manifest into AML disease (Kelly et al., 2002a; Kim et al., 
2008; Schessl et al., 2005). This hypothesis has been called the “two-hit model” of 
AML (Brandts et al., 2007; Dash and Gilliland, 2001; Kelly and Gilliland, 2002).  
The model suggests that there are two classes of mutations that are required for 
the development of AML.  Class I mutations  confer  increased  survival and 
proliferative advantage to the cells for example FLT3-ITD,  N-  or K-RAS, 
constitutively active c-kit.  Class II mutations  block  differentiation,  for  example 
AML1/ETO, PML/RARα, inv(16) or transcription factors like C/EBP alpha (Figure 4). 
Supporting this hypothesis, in a clinical setting, FLT3-ITD mutations are often found 
together with other chromosomal translocations (described in detail above in FLT3 
mutations subheading).  FLT3-ITD cooperates with PML-RARα, AML1-ETO and 
Inv(16) to develop AML in mouse models (Kelly et al., 2002a; Kim et al., 2008; 
Schessl et al., 2005).  
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Figure  2.  Two hit model of AML development.  This model hypothesizes that  AML is the 
consequence of collaboration between at least two broad classes of mutations. Class I mutations 
that cause a CML-like disease (when expressed alone). Class II mutations that lead to MDS when 
expressed alone. (Figure adopted from (Kelly and Gilliland, 2002)). 
1.4  Oncogenic tyrosine kinases implicated in leukemia 
Numerous receptor tyrosine kinases and non-receptor tyrosine kinases have been 
implicated in leukemia. Activating mutations of FLT3, c-kit and JAK2, oncogenic 
fusion proteins formed due to chromosomal translocations like   Tel-PDGFR-β, Tel-
Abl, BCR/ABL are some important examples (Blume-Jensen and Hunter, 2001).  
1.5  FLT3 (FMS-like tyrosine kinase 3) receptor  
FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase, is also called fetal 
liver kinase-2; Flk-2 or Stem cell Tyrosine Kinase-1; STK-1. FLT3 belongs to RTK 
subclass III and it is highly homologous to other subclass III members like the M-
CSF (macrophage colony stimulating factor) receptor PDGF (platelet derived 
growth factor) receptor and c-kit  receptor  (Blume-Jensen and Hunter, 2001; 
Meshinchi and Appelbaum, 2009; Stirewalt and Radich, 2003).  FLT3 is composed 
of an immunoglobulin-like extracellular ligand-binding domain, a transmembrane 
domain, a juxtamembrane dimerization domain, and a highly conserved intracellular 
kinase domain interrupted by a kinase insert (Blume-Jensen and Hunter, 2001; 
Meshinchi and Appelbaum, 2009; Stirewalt and Radich, 2003). Binding of FLT3 
ligand (FL) to extracellular domain of the receptor lead to receptor activation and     Introduction 
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downstream signaling. 
 
Figure 3: Structure of FLT3 and its activating mutations. The FLT3 receptor is comprised of an 
extracellular ligand-binding domain, consisting of five immunoglobulin-like domains, a 
transmembrane, and an intracellular split kinase domain. Binding of a FL to the FLT3  receptor 
induces dimerization of two monomers leading to auto-phosphorylation of the juxtamembrane 
tyrosines and activation of the receptor molecules. The oncogenic ITD mutations in FLT3  are 
clustered in juxtamembrane region whereas TKD mutations are present in the activation loop of the 
C-terminal kinase lobe. 
 
The predicted molecular weight of FLT3 protein based on its primary sequence is 
about 110 kDa. However, western blot analysis of FLT3 results in the two bands of 
130-143 kDa and 155-160 kDa. This difference in the calculated and actual 
molecular weight of FLT3 is due to its N-glycosylation (Lyman et al., 1993; Maroc et 
al., 1993).  
1.5.1  Expression and functions of FLT3 receptor in normal hematopoiesis 
A very small portion (about 2%) of adult human bone marrow is FLT3 positive; 
these cells represent early progenitor or stem cells (Rosnet et al., 1996). Analysis 
of FLT3 expression on human hematopoietic cell lines shows that most myeloid, 
monocytic, pro-B and pre-B cell lines are FLT3 positive, while erythroid, NK and T 
cell lines are negative (Brasel et al., 1995; DaSilva et al., 1994; Meierhoff et al., 
1995; Rosnet et al., 1996).  In mice up-regulation of FLT3  expression is 
accompanied by a loss of self-renewal capacity of stem cells and those FLT3 
positive cells have a prominent lymphoid reconstitution potential (Adolfsson et al., 
2001; Christensen and Weissman, 2001). Outside of the hematopoietic system, 
FLT3 could be detected in brain, placenta, testis, lymph nodes, thymus, and in the 
liver of adult mice (deLapeyriere et al., 1995; Rosnet et al., 1996).      Introduction 
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FLT3  has been shown to serve important functions in early hematopoietic 
progenitor proliferation and survival as well as in macrophage and dendritic cell 
differentiation (Gilliland and Griffin, 2002; Stirewalt and Radich, 2003). Mice with 
homozygous deletion of FLT3 receptor were healthy and showed normal peripheral 
blood counts (Mackarehtschian et al., 1995). However, the numbers of early B-cell 
progenitors in bone marrow of these animals were reduced compared to normal 
mice. In addition, stem cells isolated from FLT3 knockout mice are deficient in their 
ability to repopulate lymphoid and myeloid compartments when introduced into 
lethally irradiated animals (Mackarehtschian et al., 1995).  
1.5.2  FLT3 ligand 
The FLT3 ligand (FL) is a type I transmembrane protein, which is proteolitically 
cleaved to form  a soluble homodimeric protein. Although FL is  a weak growth 
stimulator  of proliferation, it strongly synergizes with other hematopoietic growth 
factors and interleukins (Broxmeyer et al., 1995; Lyman and Jacobsen, 1998).   
1.5.3  FLT3 mutations in leukemia 
FLT3  is  over-expressed in several hematologic malignancies,  including acute 
myeloid leukemia (AML), B-precursor cell acute lymphoblastic leukemia (ALL) and 
chronic myeloid leukemia (CML) in lymphoid blast crisis suggesting increased FLT3 
expression may play a role in the survival or proliferation of leukemic blasts  of 
bothmyeloid and lymphoid origion (Carow et al., 1996; Drexler, 1996).  
Activating mutations of FLT3 are present in about one third of AML cases, making 
FLT3 one of the most frequently mutated gene found in AML (Gilliland and Griffin, 
2002; Nakao et al., 1996; Schnittger et al., 2002; Stirewalt and Radich, 2003). FLT3 
mutations are also found in a small number of cases with myelodysplastic 
syndrome (MDS) or ALL (Armstrong et al., 2004; Horiike et al., 1997; Yokota et al., 
1997). Two classes of FLT3 mutations have been described. First, internal tandem 
duplications (ITD) in exon 14 and/or exon  15 of the receptor were observed in 
about 25% of AML patients. They lead to the insertion of several amino acids in the 
juxtamembrane domain (Figure 2) (Nakao et al., 1996; Steudel et al., 2003; 
Stirewalt and Radich, 2003; Thiede et al., 2002). Second, small deletions or 
insertions in the activation loop (AL) of the tyrosine kinase domain occur in 7% of 
AML patients (FLT3-TKD) (Figure 2) (Abu-Duhier et al., 2001; Thiede et al., 2002;     Introduction 
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Yamamoto et al., 2001). Most commonly, FLT3-TKD mutations involve substitution 
of aspartic acid 835 (D835) by other residues (Thiede et al., 2002). Deletion of 
I836, substitution of N841 or Y842 or insertions of single amino acids in the 
activation loop have also been found (Figure 2) (Jiang et al., 2004; Kindler et al., 
2005; Spiekermann et al., 2002a; Thiede et al., 2002). Both these above mentioned 
mutations lead to constitutive activation of the receptor. 
FLT3 activating mutations are often prevalent in patients with normal karyotype in 
leukemias (Abu-Duhier et al., 2001; Schnittger et al., 2002; Thiede et al., 2002). 
FLT3-ITD has been detected in all FAB subtypes of AML, with the highest reported 
frequency in the M3 and M5 subtype, and less  frequently in the M2 subtype 
(Gilliland and Griffin, 2002; Stirewalt and Radich, 2003; Thiede et al., 2002). The 
prevalence of FLT3-ITD in patients with AML increases with age, ranging from 5–
15% in pediatric patients to 25–35% in adults. Most studies in patients with AML 
have found that FLT3-ITD  is  a  strong, independent predictor of poor clinical 
outcome compared to FLT3-TKD mutations (Abu-Duhier et al., 2001; Iwai et al., 
1999; Kiyoi et al., 1999; Kondo et al., 1999; Schnittger et al., 2002; Thiede et al., 
2002). 
1.5.4  Activation of FLT3-WT and FLT3-ITD receptors 
Wild-type FLT3 receptor is expressed on the cell surface as a monomer and is 
inactive in the absence of its ligand FL (Weiss and Schlessinger, 1998). Binding of 
FL induces receptor dimerization  and leads to the auto-phosphorylation of the 
receptor. Ligand-induced dimerization of receptors is thought to expose tyrosine 
autophosphorylation sites and to stabilize the active conformational state, which 
further enhances the activation of the receptors (Turner et al., 1996; Weiss and 
Schlessinger, 1998). The crystal structure of the auto-inhibited form of FLT3 has 
been published (Griffith et al., 2004). The normal juxtamembrane (JM) domain, 
interacts with the kinase domain, buries the catalytic centre, and thus stabilizes the 
inactive kinase conformation. Ligand-induced dimerization and conformational 
changes lead to phosphorylation of two key JM tyrosines 589/591. This event 
destabilizes the conformation of the JM domain and allows the JM domain to move 
away from the active centre of the kinase, leading to its activation. ITD mutations in 
the  FLT3  JM domain destroy the conformational integrity of the JM domain, 
whereby the JM domain can no longer inhibit the kinase and allows the ligand-    Introduction 
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independent activation of the receptor (Griffith et al., 2004; Hubbard, 2004).  
1.5.5  Signaling and biological differences of FLT3-WT and FLT3-ITD 
Activation of the FLT3-WT receptor by FL results in the rapid phosphorylation of 
several components of the SHC/Ras/Raf/MEK/ERK pathway and PI3K/Akt 
pathways. FL stimulation is a prerequisite for the activation of FLT3-WT receptor. In 
contrast FLT3-ITD mutations constitutively activate SHC/Ras/Raf/MEK/ERK and 
PI3K/Akt pathways in a ligand independent manner. FLT3-ITD, in addition to these 
pathways, also activates STAT5 and induces expression of STAT5 target genes 
like Pim1, Pim2, SOCS2 and SOCS3 (Choudhary et al., 2005; Kiyoi et al., 2002; 
Levis et al., 2002; Mizuki et al., 2000; Schmidt-Arras et al., 2005). The detailed 
signaling differences of wild type receptor and its mutant forms are given in Figure 
3. Retroviral expression of FLT3-ITD confers factor independent growth for IL-3 
dependent 32D and Ba/F3  cell lines and support colony formation in semisolid 
media (Choudhary et al., 2005; Mizuki et al., 2000).  FLT3-ITD induces myeloid 
differentiation block by suppression of the myeloid transcription factors c/EBPα and 
Pu1 expression. FLT3-ITD also induces block of c/EBPα  function by 
hyperphosphorylation (Mizuki et al., 2000; Radomska et al., 2006). FLT3-ITD also 
confers resistance to externally induced apoptosis in 32D and Ba/F3  cells 
(Choudhary et al., 2005).      Introduction 
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Figure 3: Signaling and biological differences of FLT3-WT and FLT3-ITD. Activation mutant of 
FLT3 (FLT3-ITD) activates similar to wild type receptor activates Ras/MAPK/ERK and PI3K 
pathways. Contrasting to FLT3-WT, FLT3-ITD activates STAT5, suppresses myeloid transcription 
factors and leads to a myeloproliferative disease in mice.  
1.5.6  Mouse models for FLT3-ITD 
Injection of 32D cells expressing FLT3-ITD induced rapid development of a 
leukemia-type disease in syngeneic mice  (Mizuki et al., 2000).  Bone marrow 
transplantation with FLT3-ITD in mice leads to development of a myeloproliferative 
disease (Grundler et al., 2005; Kelly et al., 2002b). Transgenic mice expressing 
FLT3-ITD  under the control of VAV hematopoietic promoter  induced  either a 
myeloproliferative disease or a lymphoid disease (Lee et al., 2005). In a knock-in 
mouse model, FLT3-ITD developed myeloproliferative disease with a resemblance 
to chronic myelomonocytic leukemia (CMML)  (Lee et al., 2007).  In contrast,  
another knock-in mouse model for FLT3-ITD mice developed a myeloproliferative 
(Li et al., 2008). 
1.6  The Philadelphia Chromosome (BCR/ABL) 
The  Philadelphia chromosome  is a shortened  chromosome 22 resulting  from  a 
balanced translocation of the long arms of chromosome 9 and chromosome 22: t     Introduction 
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(9; 22). This translocation occurs in about 90% of CML patients and in 10-20% of 
ALL patients.  
1.6.1  BCR/ABL signaling 
The BCR/ABL fusion protein has a constitutive tyrosine kinase activity of Abl, which 
is required for BCR/ABL mediated transformation. The oligomerization domain of 
Bcr contributes to  BCR/ABL mediated transformation  (McWhirter et al., 1993).  
Imatinib mesylate is a ABL kinase inhibitor that can selectively inhibit BCR/ABL-
induced  in vitro  cell growth and in vivo  tumor formation in mice from cell lines 
expressing BCR/ABL but not from control cell lines (Druker et al., 1996). 
BCR/ABL activates multiple signaling pathways which contribute to  increased 
survival, proliferation and transformation (reviewed  by  (Wong and Witte, 2004). 
BCR/ABL constitutively activate STAT5 (prominently) and STAT1 and STAT3 to a 
less extent (Ilaria and Van Etten, 1996). BCR/ABL mediated STAT5 target genes 
A1 and Pim kinases play an important role in BCR/ABL mediated survival (Adam et 
al., 2006; Nieborowska-Skorska et al., 2002). BCR/ABL mediated STAT5 activation 
is shown to be direct and/or via HCK (Src family kinase) (Ilaria and Van Etten, 
1996; Klejman et al., 2002).  
BCR/ABL also activates PI3K/Akt via its direct association with the p85 subunit of 
PI3K (Wong and Witte, 2004).The Ras/MAPK pathway is activated by BCR/ABL via 
Grb2/Gab2 and this activation is dependent of tyrosine 177 (an auto-
phosphorylation site on BCR/ABL) (Wong and Witte, 2004). Gab2, being a critical 
mediator of PI3K/Akt and Ras/MAPK downstream of BCR/ABL, plays important role 
in BCR/ABL mediated leukemogenesis (Sattler et al., 2002).  
1.6.2  Mouse models for BCR/ABL 
Retroviral expression of BCR/ABL in mouse bone marrow cells and transplantation 
has  been  shown  to induce a myeloproliferative disorder (MPD) that closely 
resembled to CML (Daley et al., 1990; Kelliher et al., 1990). Since the transgenic 
expression BCR/ABL is embryonically  lethal, a tetracycline responsive promoter 
driven BCR/ABL transgenic mice were  generated. Using this system BCR/ABL 
expression in B-lymphocyte and megakaryocytic precursors developed B-ALL and 
megakaryocytic  myeloproliferative disease respectively (Huettner et al., 2003;     Introduction 
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Huettner et al., 2000). When the BCR/ABL is expressed in hematopoietic stem 
cells, using the  mouse stem cell leukemia (SCL) enhancer, mice developed a 
chronic-phase CML-like disease (Koschmieder et al., 2005). These mouse models 
provide significant insights into molecular pathogenesis of BCR/ABL mediated 
leukemogenesis and served as models for testing the newly developed drugs (Ren, 
2005; Wong and Witte, 2004).  
1.7  Physiological cytokine/JAK/STAT signaling pathway 
The survival and differentiation of hematopoietic stem and progenitor cells as well 
as the function of mature blood cells are under control of cytokines. Unlike RTKs 
(receptor tyrosine kinases), receptors for cytokines do not have intrinsic kinase 
activity; instead they utilize JAK kinases (Janus kinases) for signal transduction. 
Binding of cytokines  to  their cognate receptors changes the conformation and 
promotes the binding of JAKs. JAKs in turn phosphorylate the receptors as well as 
other intracellular proteins like STATs  (Signal Transducers and Activator of 
Transcription). Upon phosphorylation STAT proteins form dimers and translocate 
into the nucleus,  functioning  as transcription factors  to induce gene expression. 
There are 4 JAKs namely JAK1-3 and Tyk-2, and 7 STATs: STAT1-4, STAT5A, 
STAT5B and STAT6. Specificity of cytokine signaling is largely determined by the 
combination of activated JAKs and STATs. Depending on the JAK/STAT member 
combinations and cellular context, cytokines exert a variety of functions includes 
survival/proliferation, differentiation and apoptosis/growth arrest (Figure 5). 
Stimulation of IFNα and IFNγ receptor, leads to STAT1 and STAT2 activation by 
receptor associated JAK1, JAK2 and Tyk2. IFNα and IFNγ activated STAT1 induce 
expression of several genes involved in growth arrest, apoptosis, anti-proliferative 
and antiviral effects (Bromberg et al., 1996; Chin et al., 1997; Chin et al., 1996; 
Horvath and Darnell, 1996). On the other hand IL-3, IL-5, G-CSF, and GM-CSF 
mediated proliferative functions and neutrophilic differentiation is mediated mainly 
by STAT5 (Dong et al., 1998; Ilaria et al., 1999; Mui et al., 1995). IL-6 and G-CSF 
induced STAT3 activation plays a key role in the process of differentiation of 
macrophages and neutrophilic  granulocytes respectively (Nakajima et al., 1996; 
Shimozaki et al., 1997). Thus, functional specificity of cytokines is achieved through 
the activation of STATs and their transcriptional targets.     Introduction 
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Figure 5: Cytokine/JAK/STAT signaling pathway. Cytokines exert various functions like survival/ 
proliferation, differentiation and growth inhibition through Janus kinases mediated, STAT protein 
activation. Activated STATs form dimers and translocate into the nucleus leading to transcription 
and expression of different target genes important for either of the above-mentioned functions. 
JAK/STAT pathway is in tight regulation by negative feedback mechanisms (SOCS, PIAS and 
PTPs). Figure adopted from (Wormald and Hilton, 2004). 
Cytokine signaling in hematopoiesis and the biological implications of JAK/STAT 
pathway are extensively reviewed elsewhere (Baker et al., 2007; Levy and Darnell, 
2002; O'Shea et al., 2002). 
Activation of physiological JAK/STAT signaling pathway is under tight control by 
three major classes of negative regulators: SOCS (suppressors of cytokine 
signaling), PIAS (protein inhibitors of activated STATs) and PTPs (protein tyrosine 
phosphatases), which ensure a proper function of these pathways (Greenhalgh and 
Hilton, 2001; O'Shea et al., 2002; Wormald and Hilton, 2004). SOCS proteins are 
the major focus of the thesis and are explained in detail below.      Introduction 
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1.8  Oncogenic JAK/STAT pathway   
As discussed above activating mutations in kinases for example TEL-JAK2, TEL-
ABL, FLT3-ITD and BCR/ABL etc. are frequently found in leukemia (Blume-Jensen 
and Hunter, 2001). Several components of the  JAK/STAT pathway are often 
deregulated in leukemia. For example, activating point mutations JAK2 like V617F, 
are associated with myeloid leukemias such as polycythemia  vera,  essential 
thrombocytopenia,  idiopathic myelofibrosis  (James et al., 2005; Kralovics et al., 
2005; Levine et al., 2005).  Similarly, increased activation of STAT3 and STAT5 
which promote cell proliferation and survival were observed in leukemia patients 
(Benekli et al., 2003; Chai et al., 1997; Frank et al., 1997; Gouilleux-Gruart et al., 
1996; Spiekermann et al., 2002b).  STAT5 also play important role in the 
development of leukemia by several oncogenes. STAT5 is required for the 
development  of myelo-  and lympho-proliferative disease by Tel-JAK2 in mice 
(Schwaller et al., 2000). Constitutively active STAT5 promoted human stem cell 
self-renewal and erythroid differentiation (Schuringa et al., 2004).  Bone marrow 
transplantation of constitutively active STAT5 led to myeloproliferative disease in 
mice (Moriggl et al., 2005).  
As the major focus of the present work is FLT3-ITD and BCR-ABL, a more detailed 
description of STAT5 pathway in the context of these two oncogens is given below. 
FLT3-ITD induces strong STAT5 activation and its target genes in 32D cell line. 
STAT5 plays an important role in FLT3-ITD mediated transformation. Expression of 
dominant negative form of STAT5 in 32D-FLT3-ITD cell lines stunted the colony 
formation  (Mizuki et al., 2000). The enforced expression of FLT3-ITD in human 
CD34
+  resulted in increased self-renewal, formation of early CAs (Cobblestone 
areas) and enhanced erythropoiesis of these cells in STAT5 dependent manner 
(Chung et al., 2005). STAT5 target genes Pim1 and Pim2 play an important role in 
FLT3-ITD mediated transformation (Adam et al., 2006; Kim et al., 2005; Mizuki et 
al., 2003). Importantly, FLT3-ITD directly activates STAT5 independent of JAK or 
Src kinase, this activation is resistant to over expression of potent JAK kinase 
inhibitors SOCS1 and SOCS3, suggesting Jak kinases are not required for its 
transformation.  Similarly, Tyk2 is dispensable for FLT3-ITD mediated 
myeloproliferative disease in mice (Nakajima et al., 2006).      Introduction 
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Constitutively active STAT3 is found in multiple myeloma (MM), anaplastic large T 
cell lymphoma (ALCL). Aberrant STAT3 is also associated with erythroleukemia, 
acute lymphocytic leukemia (ALL),  chronic lymphocytic leukemia, acute myeloid 
leukemia (AML), chronic myeloid leukemia (CML), megakaryocytic leukemia 
(Catlett-Falcone et al., 1999; Epling-Burnette et al., 2001; Kirito et al., 2002; Zamo 
et al., 2002). STAT3 and STAT5 are constitutively activated by BCR/ABL. BCR/ABL 
activates STAT5 via Hck (a member of Src family kinase) (Ilaria and Van Etten, 
1996; Ren, 2005). It is has also been showed that STAT5 is directly activated by 
BCR/ABL  (Carlesso et al., 1996).  The role of STAT5 in BCR/ABL  mediated 
leukemogenesis remains controversial. Retroviral transduction of BCR/ABL  into 
bone marrow induces a CML-like MPD in STAT5 deficient mice (Sexl et al., 2000).   
Inactivation of STAT5 with siRNA in primary CML samples impairs  Ph
+ myeloid 
colony formation. Fetal liver hematopoietic progenitors from STAT5 knockout mice 
failed to induce leukemia in recipient mice after retroviral transduction with 
BCR/ABL (Hoelbl et al., 2006; Ye et al., 2006). 
1.9  SOCS proteins 
Being part of cytokine/JAK/STAT pathway,  Suppressors Of Cytokine Signaling 
(SOCS) play a major role in the regulation of cytokine responses. There are eight 
members present in SOCS family, namely SOCS1-7 and CIS (cytokine-inducible 
SH2 domain containing protein). The CIS gene was first identified as an immediate 
early response gene induced in hematopoietic cells in response to IL-2, IL-3 and 
EPO (erythropoietin) (Yoshimura et al., 1995).    Later,  three different groups 
identified SOCS1 as a novel JAK regulatory protein (Endo et al., 1997; Naka et al., 
1997; Starr et al., 1997). Based on sequence homology 6 additional SOCS proteins 
were cloned (Hilton et al., 1998; Masuhara et al., 1997; Starr et al., 1997). All 
SOCS family members have a three-part domain structure, a central SH2 domain, 
an amino-terminal domain of variable length and divergent sequence, and a 
carboxy-terminal 40-amino-acid module, known as the SOCS box.  
     Introduction 
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Figure 6: Domain structure of SOCS proteins.  SOCS Figure adopted from (Yoshimura et al., 
2007). 
The SOCS box interacts with elongin B and elongin C, cullin-5 and RING-box-2 
(RBX2) that  recruit E2 ubiquitin transferase. Thereby, SOCS  family proteins 
probably function as E3 ubiquitin ligases and mediate the degradation of proteins 
that are associated. In addition to the E3 ligase activity, SOCS1 and SOCS3 are 
shown to inhibit JAK tyrosine kinase activity directly through their kinase inhibitory 
region (KIR) that seems to function as a pseudosubstrate. 
1.9.1  Expression of SOCS proteins 
SOCS proteins are often expressed at low level to undetectable levels in 
resting/unstimulated cells. SOCS proteins are upregulated rapidly in response to a 
broad range of cytokines and in turn, control the duration and intensity of cytokine 
responses by blocking various aspects of the signaling pathways. SOCS proteins 
down-modulate the  signaling pathway, which  was responsible for their  own 
expression and hence it is a part of negative feedback mechanism (Figure 5). The 
pattern of SOCS expression by a particular cytokine varies according to the cell 
type or tissue. The induced SOCS proteins can attenuate signaling  of various 
cytokines and may be involved in inhibitory cross talk between different cytokine 
systems. SOCS can be induced by stimuli other than cytokines, including growth 
factors, chemokines, hormones, pathogens or any foreign materials like CpG DNA 
or LPS (Baetz et al., 2004; Crespo et al., 2000; Dalpke et al., 2001; Dogusan et al., 
2000; Krebs and Hilton, 2003; Leong et al., 2004; Stoiber et al., 1999). Various 
cytokine induced SOCS expression, and cytokines inhibited by different SOCS 
members are given in table1.  
1.9.2  CIS 
CIS is induced by cytokines that activate STAT5, such as Epo, GH, PRL, IL-2 and 
IL-3 and CIS induction is reported to suppress signaling cascades by masking the 
STAT5 binding sites in their receptors (Aman et al., 1999; Dif et al., 2001; Endo et     Introduction 
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al., 2003; Hansen et al., 1999; Matsumoto et al., 1997; Ram and Waxman, 1999; 
Verdier et al., 1998; Yoshimura et al., 1995). In fact, binding of CIS to erythropoietin 
receptor (EpoR)  induces proteasome-dependent degradation of the  receptor 
(Verdier et al., 1998).   
  Induced by  Inhibits signaling of 
CIS 
 
IL-1, IL-2, IL-3, IL-4, IL-6, IL-9, IL-
12, IL-13, Epo, LIF, G-CSF, GM-
CSF, TPO, IFNα, IFNγ, 
 
Epo, G-CSF, IL-2, IL-3 
SOCS1 
Epo, LIF, G-CSF, GM-CSF, 
IFNα/β, IFNγ, IL-2, IL-3, IL-4, IL-6, 
IL-13 
Epo, TNFα, OSM, TPO, IFNα/β, 
IFNγ, IL-2, IL-3, IL-4, IL-6, IL-7, IL-
12, IL-15 
SOCS2 
 EPO, G-CSF, GM-CSF, TNFα, 
LIF, IFNα, IFNγ, IL-1, IL-2, IL-3, IL-
4, IL-6, IL-9, IL-10, 
 LIF, IFNγ, IL-6 
SOCS3 
Epo, GM-CSF, M-CSF, G-CSF, 
TPO, TNFα, LIF, IFNα, IFNγ, IL-1, 
IL-6, IL-9, IL-11, IL-12, IL-13, 
Epo, OSM, LIF, IFNα/β, IFNγ, IL-2, 
IL-3, IL-4, IL-2, IL-3, IL-4, IL-6, IL-7, 
IL-9, IL-10, IL-11 
 
Table 1: List of cytokines, which induce SOCS expression and cytokines that are affected by 
SOCS expression. (Table modified from (Alexander, 2002)). 
 
CIS is also shown to bind to GHR and leads to its internalization and degradation 
(Landsman and Waxman, 2005; Ram and Waxman, 1999). CIS knockout mice are 
phenotypically normal; this was probably due to functional compensation by other 
SOCS proteins. But, CIS transgenic mice have impaired mammary gland 
development and reduced numbers of natural killer (NK); these phenotypic features 
are highly similar to STAT5 knockout mice, supporting CIS to be a specific negative 
regulator of STAT5 signaling (Matsumoto et al., 1999; Teglund et al., 1998). 
1.9.3  SOCS1 
SOCS1 directly binds to all JAK members, thereby inhibiting their kinase activity 
(Endo et al., 1997; Naka et al., 1997).  SOCS1  targets the phosphorylated 
tyrosine1007, in the activation loop of JAK2. Kinase activation of JAK2 involves 
phosphorylation of Y1007.  Although SH2 domain of SOCS1 is sufficient for JAK2 
interaction, as mentioned above, the KIR domain is required for high affinity binding     Introduction 
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and  efficient  inhibition of JAK2 activity  (Yasukawa et al., 1999).  Importantly, 
SOCS1 is shown to bind directly to the type I and type II IFN receptors, which is 
why SOCS1 shows efficient inhibitory effect on IFN signaling (Fenner et al., 2006; 
Qing et al., 2005).  
Studies on SOCS1 In vitro shows its implications on a wide range of cytokines that 
include GH, Epo, PRL, IL-3, IL-6, IFNα/β, IFNγ and IL-4 (Adams et al., 1998; Dif et 
al., 2001; Hansen et al., 1999; Song and Shuai, 1998). The potent inhibitory effects 
exhibited by SOCS1 are due to its ability to inhibit the  kinase  activity  of  JAK 
kinases.  In addition  SOCS1 induces the ubiquitination and  destruction of VAV, 
JAK2 and the TEL-JAK2 oncogene in a SOCS box dependent  fashion  (De 
Sepulveda et al., 2000; Frantsve et al., 2001; Kamizono et al., 2001; Ungureanu et 
al., 2002). SOCS1 also facilitates ubiquitin-mediated degradation MyD88 Adaptor-
Like (Mal),  thereby leading to the suppression of Mal-dependent p65 
phosphorylation and  transactivation of NF-κB  (Mansell et al., 2006; Ryo et al., 
2003).  
Very recently, the nuclear localization signal of SOCS1 has been identified; this 
signal is only present in SOCS1 among other family members. SOCS1 deficient of 
a nuclear localization signal could still inhibit IFNγ, but there is decreased IFNγ-
mediated CD54 expression (Baetz et al., 2008). This suggests many unidentified 
new roles for SOCS1.  The Role of SOCS1 in cancer is discussed below. 
SOCS1 knockout mice die within  7 to 20 days  after birth,  with a phenotype  of 
stunted growth, fatty degeneration of the liver, low mature B cells and small thymus, 
monocytic infiltration of major organs (Naka et al., 1998; Starr et al., 1998). These 
multiple deregulations of the immune system were attributed to uncontrolled IFNγ 
signaling leading to constitutive STAT1 activation. In support of  this, knocking out 
IFNγ  gene  or  administration  of  neutralizing  anti-IFNγ  antibodies  prevented 
phenotype of SOCS1 knockout mice (Alexander et al., 1999; Marine et al., 1999b). 
SOCS1 conditional knockout mice demonstrated an inhibitory role for SOCS1 on 
IL-2 or IL-7 (Chong et al., 2003; Cornish et al., 2003). SOCS1 transgenic mice are 
characterized by defective thymocyte development and perturbed homeostasis of T 
cells (Fujimoto et al., 2000).      Introduction 
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1.9.4  SOCS2 
SOCS1 interaction with phosphotyrosine motifs on the GHR, PRLR, EGFR, EpoR 
and LR has been reported. SOCS2 act as an ubiquitin ligase and appeared to be 
crucial for the negative regulation of GH signaling  (Eyckerman et al., 2001; 
Goldshmit et al., 2004; Greenhalgh et al., 2005; Lavens et al., 2006; Pezet et al., 
1999). Mice lacking SOCS2 exhibit gigantism associated with increases in bone 
and body  length and enhanced weight of organs due to uncontrolled growth 
hormone induced STAT5 (Greenhalgh et al., 2002; Metcalf et al., 2000). 
1.9.5  SOCS3 
Although SOCS3 is structurally very similar to SOCS1, it exerts a very different 
effect. SOCS3 is known to interact with gp130, LR, EpoR, LIFR, IL-6R, IL-12R and 
GHR (Bjorbak et al., 2000; Hortner et al., 2002; Lehmann et al., 2003; Ram and 
Waxman, 1999; Yamamoto et al., 2003). Deletion of the SOCS box of SOCS3 in 
transgenic mice leads to impaired regulation of G-CSF signaling and response to 
inflammatory stimuli, establishing a role for the SOCS box in the in vivo actions of 
SOCS3  (Boyle et al., 2007). SOCS3 not only controls the  magnitude of IL-6 
signaling but also shapes IL-6 responses. IL-6 loses its pro-inflammatory function 
and elicits immunosuppressive actions  in SOCS3 deficient macrophages 
(Yasukawa et al., 2003). Also, IL-6 strongly activates STAT1, thereby inducing the 
expression of IFN-responsive genes in SOCS3 deficient macrophages (Croker et 
al., 2003; Lang et al., 2003). 
Both SOCS3 knockout and transgenic mice die in utero. The lack of SOCS3 leads 
to uncontrolled LIF signaling in placental tissue. Transgenic SOCS3 expression in 
mice results in defective fetal liver erythropoiesis (Marine et al., 1999a; Roberts et 
al., 2001; Takahashi et al., 2003). Studies in conditional SOCS3 knockout mice 
demonstrated that SOCS3 is an important negative regulator of GCSF (Croker et 
al., 2004; Kimura et al., 2004) and IL-6 (Croker et al., 2003; Lang et al., 2003; 
Yasukawa et al., 2003). 
1.9.6  SOCS4-7 
SOCS4, 5, 6 and 7 are  the least studied among other SOCS family members 
SOCS4 and SOCS5 are highly up regulated upon EGF (epidermal growth factor) 
stimulation and leads to EGFR (epidermal  growth  factor  receptor) degradation     Introduction 
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(Kario et al., 2005).  SOCS6 is induced by insulin, SCF (stem cell factor or Kit 
Ligand) and it interacts with the insulin receptor, KIT receptor (Bayle et al., 2004; Li 
et al., 2004; Mooney et al., 2001).  SOCS7 can suppress PRL, GH  and leptin 
signaling by interacting with STAT5 or STAT3 and preventing their nuclear 
translocation (Martens et al., 2005). 
1.10 SOCS proteins in cancer 
SOCS1 has been shown to have tumor suppressor properties. SOCS1 blocks the 
oncogenicity of several hematopoietic specific oncogenes such as the constitutively 
active form of the KIT receptor, TEL-JAK2, v-ABL, oncogenic form of VAV and 
partially BCR/ABL (De Sepulveda et al., 2000; Rottapel et al., 2002). Inactivating 
mutations of SOCS1 were found in Hodgkin lymphoma and were associated with 
higher JAK2 expression, STAT6 activation and nuclear accumulation of phospho-
STAT5 (Mottok et al., 2007; Weniger et al., 2006). The SOCS1 gene is found to be 
hyper-methylated in hepatocellular carcinoma, multiple myeloma, pancreatic cancer 
and liver carcinomas (Galm et al., 2003; Komazaki et al., 2004; Yoshikawa et al., 
2001) Constitutive activation of the JAK-STAT pathway in several hematological 
malignancies including leukemia and lymphoma are also  associated with SOCS 
down regulation (Galm et al., 2003; Watanabe et al., 2004; Weniger et al., 2006). 
Since SOCS proteins appear to have tumor suppressor functions that need to be 
bypassed for transformation to occur (Limnander et al., 2004). CIS and SOCS1 
expression with BCR/ABL reduced its oncogenic potential (Rottapel et al., 2002; 
Tauchi et al., 2001).  This implies that the forced expression of SOCS might be 
beneficial for the treatment of some malignancies (Frantsve et al., 2001; Rottapel et 
al., 2002). 
SOCS  expression is induced by oncogenic kinases BCR/ABL and FLT3-ITD. 
SOCS2 overexpression  was clearly found to correlate with advanced stages of 
chronic myeloid leukemia (CML) and this expression was abrogated by imatinib 
treatment  (Schultheis et al., 2002; Zheng et al., 2006)  Mizuki et al. also found 
SOCS2 and SOCS3 to be up regulated by FLT3-ITD in 32D cells (Mizuki et al., 
2003).  
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2  Objectives 
2.1  Hypothesis 
FLT3-ITD, an activating mutation of FLT3, is one of the most frequent mutations 
found in AML patients.  Unlike FLT3-WT, FLT3-ITD activates STAT5 and its targets 
Pim kinases and SOCS proteins, which play a key role in transformation (Mizuki et 
al., 2000). Importantly STAT5 target genes like Pim kinases play a crucial role in 
FLT3-ITD mediated transformation (Adam et al., 2006; Grundler et al., 2009). FLT3-
ITD directly activates STAT5 independently of JAK or Src kinases therefore the 
activation is resistant to physiological negative feedback mediated SOCS proteins 
(Choudhary et al., 2007).  Hence we hypothesize  that these FLT3-ITD-induced 
SOCS genes, lead to escape from external cytokine control, thereby promoting the 
leukemogenesis.  SOCS proteins are known for their growth inhibitory functions; 
especially SOCS1 is shown to be a tumor suppressor in the context of several 
oncogenes  (Rottapel et  al., 2002; Yoshimura et al., 2007).  The role of SOCS 
proteins in FLT3-ITD mediated leukemogenesis remains  unexplored. Hence 
studying the role of SOCS proteins in the molecular pathogenesis of FLT3-ITD may 
provide their prognostic importance and help to find new therapeutic targets.  
2.2  Specific objectives  
•  To study FLT3-ITD induced SOCS gene expression in primary bone marrow 
and in blasts from AML patients. 
•  To study the role of SOCS proteins in FLT3-ITD mediated transformation in 
vitro and leukemogenesis in vivo. 
•  To determine if SOCS proteins play a general role in the context of other 
oncogenes such as BCR/ABL.     Materials and Methods 
 
 
3  Materials and Methods 
3.1  Materials 
3.1.1  Instruments and apparatus 
FACS Machine  FACScan and FACS Canto  II  Becton 
Dickinson, Heidelberg 
Cytocentrifuge  Thermo Shandon, Pittsburgh, US 
Cytofunnel  Shandon, Pittsburgh, USA 
Irradiation of mice-Betatron 500A  Siemens, Munich, Germany 
Magnetic cell separation  Miltenyi, Bergisch Gladbach, Germany 
Agarose gel apparatus  Biometra, Goettingen, Germany 
SDS-PAGE apparatus  XCell SureLock™ Mini-Cell,  Invitrogen, 
Karlsruhe, Germany 
Gene Pulser system (electroporation)  Bio-Rad Laboratories, Munich, Germany 
Axio-Cam up-right Microscope  Zeiss, Goettingen, Germany 
Fast Real-Time PCR System (7900HT)  Applied Biosystems, Foster City, CA 
3.1.2  Kits 
Plasmid mini-prep Kit  Zymo Research, Freiburg, Germany 
Gel-DNA recovery Kit  Zymo Research, Freiburg, Germany 
Plasmid-Maxi-prep Kit  Genomed, Loehne, Germany 
TRIzol-RNA isolation Kit  Invitrogen, Karslruhe, Germany 
Luminol reagent  Santa Cruz Biotechnology (Santa Cruz, 
CA) 
Bone marrow lineage cell depletion kit  Miltenyi, Bergisch Gladbach, Germany 
Sca-1 isolation kit  Miltenyi, Bergisch Gladbach, Germany     Materials and Methods 
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3.1.3  Chemokines and cytokines 
rmG-CSF          Peprotech, (Rocky Hill, NJ, USA) 
rmSCF          Peprotech, (Rocky Hill, NJ,USA) 
rmIL-6           Peprotech, (Rocky Hill, NJ,USA) 
rmIL-3           Peprotech, (Rocky Hill, NJ, USA) 
rmIFNα          R&D systems(MinneapolisUSA) 
rmIFNγ  Sigma Aldrich (Taufkirchen, Germany) 
3.1.4  Enzymes 
Calf intestinal phosphatase (CIP)  New England Biolabs, Frankfurt, Germany  
Gateway LR clonase enzyme mix  Invitrogen, Karslruhe, Germany 
Klenow-Fragment DNA-polymerase-I   NEB, Frankfurt, Germany             
Restriction endonucleases  NEB, Frankfurt, Germany           
RNAse  Sigma, Steinheim, Germany 
T4 DNA-ligase  NEB, Frankfurt, Germany 
Taq-DNA-polymerase      Biosystems, Weiterstadt, Germany 
Proteinase K         Stratagene, La Jolla, USA 
3.1.5  Primary antibodies used for western blotting 
Mouse anti-p-STAT5- Y694    Biotechnology (Lake Placid, NY) 
Anti-phosphoErk1/2-T202/Y204  Cell Signaling (Beverly, MA) 
Anti-phosphoFLT3-Y591   Cell Signaling (Beverly, MA) 
Anti-phosphoSTAT1-Y701  Cell Signaling (Beverly, MA) 
Anti-phosphoAkt-S473  Cell Signaling (Beverly, MA) 
Anti-Erk1/2  Santa Cruz Biotechnology (Santa Cruz, 
CA)     Materials and Methods 
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Anti-STAT5a/b  Santa Cruz Biotechnology (Santa Cruz, 
CA) 
Anti-GFP  Santa Cruz Biotechnology (Santa Cruz, 
CA) 
Anti-Pim1  Santa Cruz Biotechnology (Santa  Cruz,
  CA) 
Anti-Pim2  Santa Cruz Biotechnology(Santa  Cruz,
  CA) 
Anti-β Actin    Sigma Aldrich (Taufkirchen, Germany) 
Anti-SOCS1     MBL (Freiburg, Germany). 
3.1.6  Secondary antibodies 
Anti-mouse IgG-HRP  Jackson immune research Labs Inc. 
Hamburg, Germany 
Anti-rabbit IgG-HRP       Jackson immune research Labs Inc. 
            Hamburg, Germany 
3.1.7  FACS antibodies 
Rat-anti- mouse-PE-Gr-1      (Becton Dickinson, Heidelberg,   
            Germany) 
Rat-anti- mouse-PE-Mac-1     (Becton Dickinson, Heidelberg,   
            Germany) 
Rat-anti- mouse-PE-B220      (Becton Dickinson, Heidelberg,   
            Germany) 
Mouse-anti-PE-IgG 2a, K      (Becton Dickinson, Heidelberg,   
            Germany) 
Mouse-anti-PE-IgG 2b, K      (Becton Dickinson, Heidelberg,   
            Germany)     Materials and Methods 
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Rat –anti-Mouse-PE-Sca-1      (Becton Dickinson, Heidelberg,   
            Germany) 
Rat-anti- mouse-PE-kit      (Becton Dickinson, Heidelberg,   
            Germany) 
Rat-anti- mouse-PE-CD3e     (Becton Dickinson, Heidelberg,   
            Germany) 
Rat-anti- mouse-PE-CD4      (Becton Dickinson, Heidelberg,   
            Germany) 
3.1.8  Cell culture media and reagents 
BSA  solution        Sigma, Steinheim, Germany 
Chloroquine          Sigma, Steinheim, Germany 
DMEM, -High glucose (4.5g/l)    Invitrogen, Karlsruhe, Germany 
DMSO          Sigma, Steinheim, Germany 
FBS            Gibco BRL, Paisley, Schottland 
Ficoll separating solution      Biochrom, Berlin, Germany 
HBSS           Gibco, Karlsruhe, Germany 
HEPES solution        Gibco, Karlsruhe, Germany 
Imatinib          Novartis, Basel, Switzerland 
PKC412          Novartis, Basel, Switzerland 
IMDM           Gibco, Karlsruhe, Germany 
L-Glutamine          Gibco, Karlsruhe, Germany 
Methylcellulose (M3434, M3231)  StemCell Technologies, Vancouver, 
Canada 
PBS            Gibco, Karlsruhe, Germany 
Penicillin-Streptomycin solution    Gibco, Karlsruhe, Germany     Materials and Methods 
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Retronectin          Takara, Shiga, Japan 
RPMI 1640          Gibco, Karlsruhe, Germany 
Trypan blue stain (0.4%)      Gibco, Karlsruhe, Germany 
Trypsin-EDTA, 0.25% solution    Gibco, Karlsruhe, Germany 
β-mercapto-ethanol       Fluka , Deisenhofen, Germany  
3.1.9  Bacteria 
E. coli (DH5α, BL21, JM83, DB 3.1)  Invitrogen, Karlsruhe, Germany 
3.1.10 Cell lines 
32D cells      IL-3 dependent mouse (C3H/HeJ   
    strain)  bone marrow progenitor cell 
    line 
Ba/F3 cells          IL-3 dependent mouse (Balb/c strain) 
            pro-B cell line, established from    
            peripheral blood 
Platinum-E cells        293T cell based ecotropic retroviral 
            packaging cell line 
SC1 cells          Mouse fibroblast cell line 
MV4-11 cells         FLT3-ITD positive acute monocytic 
             leukemia (AML-M5) cell line    
            established from a patient 
MOLM-13 cells        FLT3-ITD positive acute myeloid     
            leukemia (AML-M5a) cell line    
            established from a patient 
K-562 cells       BCR/ABL positive cell line     
     established from a chronic myeloid 
      leukemia (CML-blast crisis) patient     Materials and Methods 
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Sup-B15 cells        BCR/ABL positive cell line    
             established from bone marrow of an 
            acute lymphoblastic leukemia    
            (precursor B cell-ALL) patient 
3.1.11 Long-term cultured primary lymphoblastic leukemia cells from  
patients 
3.1.11.1  Ph
+ Patients (Philadelphia chromosome positive): 
BV, CM, WD, KW, PH and VB (these are the patient initials) (Nijmeijer et al., 2009). 
3.1.11.2  Ph
- Patients (Philadelphia chromosome negative): 
VG, KR, RL,  SK, CR and HP (these are the patient initials) (Nijmeijer et al., 2009). 
3.1.12 Mice   
Female Balb/c mice (aged between 4-8 weeks) were purchased from Charles River 
Laboratories GmbH in Munich, Germany.  
3.1.13 Patient samples 
Samples were collected from patients enrolled in
 a treatment optimization trial in 
Germany.
 Control total bone
 marrow samples were obtained from healthy donors. 
Written informed
 consent was obtained from all individuals. The ethics committee of 
the Medical Faculty of the University of Muenster approved the use of patient 
samples.     Materials and Methods 
 
  28 
3.2  Methods 
3.2.1  Cell culture 
32D, Ba/F3 cell lines were cultured in RPMI1640 medium supplemented with 10% 
FCS, 10%WEHI conditioned medium (IL-3 source) and 1% Penicillin and 
streptomycin.   
MV4-11, MOLM-13, K562 and Sup-B15 cell lines were cultured in RPMI1640 
medium supplemented with 10% FCS and 1% Penicillin and streptomycin.  
Platinum-E and SC-1 cell lines were cultured in DMEM medium supplemented with 
10% FCS and 1% Penicillin and streptomycin. 
BV, CM, WD, KW, PH, VB, VG, KR, RL, SK, CR and HP cells were cultured in 
IMDM  medium  supplemented  with  1  μg/mL  bovine  insulin,  0.5  μM  β-mercapto-
ethanol,  200  μg/mL  Fe3+-saturated human apo–transferrin, 0.6% human serum 
albumin, 2.0 mM L–glutamine and 20 μg/mL cholesterol as described previously 
(Nijmeijer et al., 2009). 
3.2.2  RNA preparation, quantitative PCR (polymerase chain reaction) 
The TRIzol method was used for RNA isolation as described by the manufacturer 
(Invitrogen). RNA was accurately quantified using spectrophotometer. Equal 
amounts of RNA were used for making cDNA according to the protocol provided by 
manufacturer (Fermentas). Prior to cDNA synthesis, all RNA samples were treated 
with DNAse to prevent genomic DNA contamination. Real time quantitative PCR is 
done using probe master mix from Fermentas. Endogenous control assay kits from 
Eurogentech for GAPDH, 18S rRNA, RNA polymerase IIa, beta Actin were used for 
normalization of the expression. A list of all the primers and probes used is given 
below. Unless stated otherwise, all the probes used in the study were 5’-FAM and 
3’BHQ1 labelled. 
Murine CIS:  
Probe       -   TCTATTACAGCCAGCGAGGCCCGG 
Primer Forward (FW)   -   CGGGAATCTGGGTGGTACTG 
Primer Reverse (REV)  -  ACCCTCCGGCATCTTCTGTA 
Murine SOCS1:  
Probe       -   TGGCGCGCATCCCTCTTAACCC     Materials and Methods 
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Primer (FW)      -   CCGTGGGTCGCGAGAAC 
Primer (REV)     -   AAGGAACTCAGGTAGTCACGGAGTAC 
Murine SOCS2: 
Probe       -  CAGGCCCAGAAGCCCCACGG 
Primer (FW)      -   TCCAGATGTGCAAGGATAAACG 
Primer (REV)     -   GGTTTGGTCAGGTACAGGTGAAC 
Murine SOCS3: 
Probe       -  ACTGTCAACGGCCACCTGGACTCCT 
Primer (FW)      -  CCACCCTCCAGCATCTTTGT 
Primer (REV)     -  CAGGCAGCTGGGTCACTTTC 
Murine SOCS4: 
Probe       -   CACTCCCTTAATCCGGACGTTCCCC 
Primer (FW)      -  TGTTCTTTGAGCCGCTCTTGT 
Primer (REV)     -  TGCAAATATGCTGCAAGGAAA 
Murine SOCS5: 
Probe       -   CTGTGCCGCAGAGATCCCTCAAGTG 
Primer (FW)      -  TTTCCAGGCGGAACCAAA 
Primer (REV)      -  TGTCTTTCTCGATGCTGATTTCA 
Murine SOCS6: 
Probe       -   TGGCCTCTCGGGCCCAGACTT 
Primer (FW)      -  AACCCAATCCAAAGGAACTTCA 
Primer (REV)      -  CGAACACTTTCGGCCATGT 
Murine SOCS7: 
Probe       -   ACCCCACGCCCCAGATGCGT 
Primer (FW)      -  TTGCAGTCTTTCCCCCTACCT 
Primer (REV)      -  ACGCTCTGATGGGAGCAATT 
Human CIS: 
Probe       -   TCTGCTGTGCATAGCCAAGACCTTCTCC 
Primer (FW)      -  CAGACAGAGAGTGAGCCAAAGGT  
Primer (REV)      -   ACCCCAATACCAGCCAGATTC     Materials and Methods 
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Human SOCS1: 
Probe       -  CTTAGCGTGAAGATGGCCTCGGGA 
Primer (FW)      -  CCAGCGGAACTGCTTTTTC 
Primer (REV)      -  GCTGCCATCCAGGTGAAAG 
Human SOCS2: 
Probe       -  ACCAAACCGCTCTACACGTCAGCACC 
Primer (FW)      -  GAACGGCACTGTTCACCTTTATC 
Primer (REV)      -  GCCTACAGAGATGCTGCAGAGA 
Human SOCS3: 
Probe       -  CCTTCAGCTCCAAGAGCGAGTACCAGC 
Primer (FW)      -  CCAGCCTGCGCCTCAA 
Primer (REV)      -  CTTGCGCACTGCGTTCAC 
Human SOCS4: 
Probe       -  TTCCAGAAAAAGAAACAAACCCAAA   
          TGGGA 
Primer (FW)      -  GAAGATAGTGATATGGATTCCGATGA 
Primer (REV)      -  TGTTTCCAACTGCAGGATTTCA 
Human SOCS5: 
Probe       -  ACTACCTCTTCTCTGTGAGCTTCCGCCG 
Primer (FW)      -  CAGGGACTCTGCGCAAGAG 
Primer (REV)      -  CGGGCATGCAGGGATCT 
Human SOCS6: 
Probe       -  CGTGCCAGGAGCAAGCCAATTCA 
Primer (FW)      -  TCCACGACCTCCAGTCTGAGA 
Primer (REV)      -  ATTATGAGAAGCCGAGCTCTTCA 
Human SOCS7: 
Probe       -  AGCACCTTTGCAGATTCCGGATACGA 
Primer (FW)      -  CCCGATTCAGCAATGTCAAA 
Primer (REV)      -  AGAGGTTTAGGCAGTGGGAGATC     Materials and Methods 
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3.2.3  Plasmids and Cloning  
pMY-IRES-GFP 
A MMLV/MESV based retroviral vector was a kind gift from T. Kitamura and is very 
useful in producing high titer retrovirus.(Kitamura et al., 2003).   
pMY-SOCS1-IRES-GFP 
Murine SOCS1 cDNA is cloned into pMY-IRES-GFP BamHI and KpnI sites. 
pMY-FLT3-ITD-IRES-GFP 
Human FLT3-ITD cDNA is cloned into pMY-IRES-GFP in NotI site. 
pMY-SOCS1-T2A-FLT3-ITD-IRES-GFP 
SOCS1-T2A PCR product with 5’ SacII and 3’ Cla1 was directly cloned into pMY-
FLT3-ITD-IRES-GFP in frame to generate pMY SOCS1-T2A-FLT3-ITD-IRES-GFP. 
T2A is a self-cleaving peptide sequence that enables the cleavage of SOCS1 and 
FLT3-ITD by a ribosomal skip mechanism without affecting the translation either 
proteins (Szymczak et al., 2004).  
pMY-SOCS1-FLAG-IRES-GFP 
Quick-change mutagenesis was performed using the primers (sequences are given 
below) to introduce FLAG tag, STOP codon and a Not1 site on C-terminus of 
SOCS1. KpnI and NotI released fragment of SOCS1-FLAG is cloned into pENTR1 
vector. pENTR1A SOCS1-FLAG was digested with BamH1, Not1 and then finally 
ligated into pMY-IRES-GFP.  
Flag-SOCS1 STOP Not I forward primer:  
CCTTCCCCTTCCAGATCTGAGCGGCCGCGAGGGCAGAGG 
Flag-SOCS1 STOP Not I forward primer:  
CCTCTGCCCTCGCGGCCGCTCAGATCTGGAAGGGGAAGG 
pMY-BCR/ABL-HA-IRES-GFP 
Oligos for HA sequence with restriction sites, SacII on 5’ and FseI site on the 3’ end 
were annealed and ligated inframe with BCR/ABL  into pENTR-BCR/ABL  vector 
(kind gift from Martin Ruthardt’s group) digested with SacII and FseI enzymes. 
BCR/ABL-HA fragment is released by digesting with EcoRI and ligated into pMY-    Materials and Methods 
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IRES-GFP (that is digested EcoR1 and 5’ dephosphorylated with calf intestinal 
alkaline phosphatase).  
SacII HA FseI forward primer:  
GGATCTGATGCCGCGGATTATGGCATACCCATACGATGTTCCAGATTACGCGG
CCGGCCTGGCGTGCGA 
SacII HA FseI reverse primer: 
TCGCACGCCAGGCCGGCCGCGTAATCTGGAACATCGTATGGGTATGCCATAA
TCCGCGGCATCAGATCC 
pMY-SOCS1-FLAG-T2A-BCR/ABL-HA-IRES-GFP 
SOCS1-FLAG-T2A with SacII site on 5’ side and FseI site on 3’ side was PCR 
amplified and cloned in-frame into SacII and FseI linearized pENTR-BCR/ABL-HA 
to create pENTR-SOCS1-FLAG-T2A-BCR/ABL-HA-IRES-GFP. Finally,  SOCS1-
FLAG-T2A-BCR/ABL-HA is released using EcoRI site and ligated into pMY-IRES-
GFP vector (that is digested EcoR1 and 5’ dephosphorylated with calf intestinal 
alkaline phosphatase), generating pMY-SOCS1-FLAG-T2A-BCR/ABL-HA-IRES-
GFP. 
 
Figure 7: Schematic depiction of various plasmid vectors used in the study. 
 
3.2.4  Generation of stable 32D and Ba/F3 cell lines 
32D and Ba/F3 cells were transduced with pMY-empty (GFP control), FLT3-ITD, 
SOCS1-T2A-FLT3-ITD retroviral supernatants in the presence of polybrene three 
times a day for two consecutive days. Then cells were sorted for GFP. Sorted bulk-
cultures were used for analyzing proliferation assay and signaling. These cells were 
also used to study Interferon mediated STAT1 activation.     Materials and Methods 
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3.2.5  3[H]-thymidine incorporation assay 
A total of 2 x 10
4  32D cells were starved from IL-3 and incubated in medium 
containing 0.5% FCS for 12 hours in 200µL medium in a 96-well plate. 
Subsequently, cells were placed in medium with 10% FCS, supplemented with the 
indicated concentrations of 100 nM PKC412, 2 ng/mL IL-3, 1000 U/mL IFNα and 
100 ng/mL IFNγ. The PKC412, wherever used, was added 1 hour prior to addition 
of growth factors.  Addition of radio-labeled 3(H)-thymidine and measurement of 
incorporation was  done as previously described (Choudhary et al., 2005).  Each 
data point represents the mean and the SD of 3 independent experiments and each 
experiment is the average of quadruplicates of every condition.  
3.2.6  Competitive proliferation assay by FACS 
32D cells were tranduced with control (GFP), SOCS1, FLT3-ITD and SOCS1-T2A-
FLT3-ITD retrovirus. These mixed population of transduced (GFP) and un-
transduced cells (no GFP) were either cultured in the presence or absence of IL-3. 
Selective advantage or disadvantage of transduced cells was monitored by 
measuring the percentage of GFP
 positivity by FACS. 
3.2.7   Stimulation of cells 
Stable cell lines (mentioned above) were washed three times with PBS and starved 
overnight in RPMI medium containing 0.5% serum. The next morning cells were 
either stimulated for 15 minutes with IFNα (1000 U/mL) or with IFNγ, (100 ng/mL) 
or left unstimulated. Protein lysates were made as described below. 
3.2.8  Western blotting 
Cells were harvested and washed once with ice-cold PBS and lysed with buffer 
containing 50 mM HEPES (N-(2-Hydroxyethyl) piperazine-N′-(2-ethanesulfonic 
acid)), 10% glycerol, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA 
(ethylenediaminetetraacetic acid), 1 mM EGTA (ethylene glycol tetra acetic acid), 
50 µM ZnCl2, 25 mM NaF, proteinase inhibitors, 1 µM pepstatin, and 1 mM sodium 
orthovanadate. After incubation on ice for 30 minutes, cell lysates were centrifuged 
at 14000 rpm for 10 minutes at 4°C. Equal amounts of protein was resolved by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to Immobilon P membranes (Millipore, Bedford, MA) and probed with     Materials and Methods 
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the indicated antibodies. Immunodetection was done using luminol reagent from 
Santa Cruz Biotechnology. 
3.2.9  Flow cytometry  
Single-cell suspensions of peripheral blood or tissue, bone marrow samples were 
prepared and red blood cells were lysed prior to analysis. Nucleated cells were pre-
incubated with Fc-block and subsequently stained with phycoerythrin (PE)-
conjugated anti-CD19, anti-B220, anti-Gr-1, anti-CD117 (KIT) antibodies and 
analyzed on FACS Scan.  
3.2.10 Primary murine bone marrow 
Balb/c mice were injected with 150 µg of 5-flurouracil / gram body weight of the 
mouse and after 3 days mice were sacrificed and bone marrow were harvested. 
Cells were pre-stimulated overnight in Iscove modified Dulbecco medium (IMDM 
medium) supplemented with 20% FCS with mSCF (50 ng/ml), mIL-3 (10 ng/ml), 
hIL-6 (10 ng/ml) and 100µM β-mercapto-ethanol. 
3.2.11 Retroviral supernatants and transduction of murine bone marrow 
All retroviral vectors (pMY empty, pMY mSOCS1, pMY FLT3-ITD, pMY SOCS1-
T2A-FLT3-ITD were transfected into the Plat-E packaging cell line with 
lipofectamine and Plus reagent (Invitrogen) according to manufacturer instructions. 
Supernatants were collected after 36 hours for every 12 hours until 60 hours. The 
retroviral supernatants were tested for titer on SC1 cells. Retroviral supernatants 
with equal titers were coated on RetroNectin pre-coated 6-well plates according to 
manufacturer instructions. The bone marrow cells were seeded overnight in equal 
numbers in corresponding wells and transferred to freshly coated wells for 2 
consecutive days. The cells were FACS-analyzed for GFP expression.  
3.2.12 Colony assay of murine bone marrow cells 
Retrovirally transduced bone marrow was sorted for GFP. These GFP+ cells were 
washed three times with PBS and 2000 cells were plated in 1 mL of methylcellulose 
per dish in triplicates. Methylcellulose was either  supplemented  with  IFNγ  (100 
ng/mL) (Methocult #3231) or contained 50 ng/mL of mSCF, 10 ng/mL of mIL-3 and 
10 ng/mL of hIL-6 (Methocult #3534). Colonies were counted after 12 days and 
equal number of cells (2000 cells/ml) from colony assay were serially replated.     Materials and Methods 
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3.2.13 Transplantation of murine bone marrow and assessment of mice 
The bone marrow was resuspended in PBS and 2 x 10
4 GFP-positive cells (at least 
1.5X 10
5 propidium iodide negative cells in total) were injected into the tail veins of 
lethally irradiated (8 Gy) female Balb/c recipient mice. In total, the groups were pMY 
(empty vector, n = 7), pMY SOCS1 (n = 10), pMY FLT3-ITD (n = 6) and pMY 
SOCS1-T2A-FLT3-ITD (n = 10). Blood counts of the peripheral blood of 
transplanted animals were monitored on day 10, 20 and 30 on a Hemavet 950 
(DREW Scientific, Oxford, Connecticut, USA) and by FACS analysis for GFP 
expression. All moribund mice were sacrificed and peripheral blood, bone marrow 
and spleen cells were analyzed for GFP and for CD19, CD117 and Gr-1 surface 
markers. At the end of the experiment (day 120) all remaining mice were sacrificed 
and analyzed. The experimental protocols were reviewed and approved by the 
local Committee on Animal experimentation. 
3.2.14 Cytospin preparations and Wright Giemsa staining 
Cytospins of single cell suspensions were performed by resuspending cells in PBS 
at a concentration of 2-6x10
5 cells per 200 μl. The cells were permanently fixed on 
glass slides by centrifugation at 500 rpm for 10 minutes and subsequently air-dried. 
Modified Wright Giemsa staining was performed by immersing the slides in May-
Gruenwald solution stain for 5 minutes. This was followed by immersing the slides 
in 1:50 diluted Giemsa stain for 1 hour. Slides were dipped in water to remove 
excess stain between the two staining steps and after the staining procedure and 
air-dried. These slides were observed under the inverted light microscope (as 
described below). 
3.2.15 Histology and Microscopy 
Organs were formalin fixed, paraffin embedded and 4-6µm sections were stained 
with hematoxylin and eosin stain (H&E) for histopathologic analysis. The 
representative images were acquired an Axio Cam camera (Zeiss) and Axiovision 
4.0 software (Zeiss) at room temperature with Zeiss upright microscope system 
(Zeiss, Thornwood, NY), the original magnification of 50X and 400X for spleen and 
100X and 400X for liver and sternum bone marrow.     Materials and Methods 
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3.2.16 Software and Statistics 
The CellQuest Version 3.1(f) and FACS Diva (BD Biosciences, Palo Alto, CA) were 
used for FACS experiments. Calculations of survival curve, t-tests were performed 
using GraphPad Prism version 5 (Graph Pad Software, San Diego California, USA). 
The ABI Prism 310 sequencing software (Applied Biosystems, Foster City, CA) was 
used for sequencing and analysis of sequences. Primers were designed using the 
Primer3 program, Whitehead Institute, Massachusetts Institute for Technology, MA. 
Quantification of relative mRNA expression was performed using SDS version 2.3 
software (Applied Biosystems, Foster City, CA). Primers probes for quantitative real 
time PCR were designed using Primer express Version 3 (Applied Biosystems, 
Foster City, CA). Bone marrow/ blood smears and histological images were 
acquired and processed using Axiovision 4.0 software (Zeiss, Thornwood, NY). 
Microsoft office 2007, Endnote version X2, Adobe illustrator creative suite 4 were 
used to make figures, write thesis and manuscript.  
     Results 
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4  Results 
4.1  Role of SOCS1 in FLT3-ITD mediated leukemogenesis 
4.2  Retroviral expression of FLT3-ITD in 32D, Ba/F3 and murine bone 
marrow induced SOCS gene expression 
Previous reports have shown that FLT3-ITD activates STAT5 and induces its target 
genes like SOCS2 and SOCS3 expression in a microarray experiment (Mizuki et 
al., 2003). To confirm previous results and to further analyze the induction SOCS 
gene expression by FLT3-ITD, mRNA expression of SOCS family members in 32D, 
Ba/F3 and in primary murine bone marrow retrovirally expressing FLT3-ITD was 
comprehensively analyzed. 
4.2.1  Ectopic expression FLT3-ITD induced CIS, SOCS1-2 expression in 
hematopoietic cell lines 
 
Figure  8:  FLT3-ITD induced CIS, SOCS1-3 gene expression in 32D, Ba/F3 cell lines.   
32D and Ba/F3 stable cell lines expressing either FLT3-ITD or an empty GFP vector (control) were 
starved overnight of IL-3 and FCS. The expression of CIS, SOCS1-3 transcripts is measured by 
quantitative PCR as describe in methods. (A) Normalized expression of CIS, SOCS1-3 in 32D-
FLT3-ITD cell line and (B) Normalized expression of CIS, SOCS1-3 in Ba/F3-FLT3-ITD cell line. 
Standard deviations are presented as error bars. (* p<0.05, ** p<0.01)  
32D and Ba/F3 cell lines were transduced with a pMY-FLT3-ITD-IRES-GFP or an 
empty  vector (pMY-IRES-GFP). Retroviral vector -pMY in combination with 
platinum-E cells has been shown to produce high titer virus and the IRES driven 
GFP expression enabled tracking and purification of transduced cells (Kitamura et 
al., 2003; Morita et al., 2000)  In all experiments, GFP expressing empty vector 
transduced cells were used as controls. Cells were washed of IL-3 and were     Results 
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cultured overnight in 0.1% FCS, RNA was extracted and relative expression of CIS, 
SOCS1, SOCS2 and SOCS3 was measured by real-time PCR. In both 32D and 
Ba/F3 cell lines, FLT3-ITD induced high expression of CIS, SOCS1 and SOCS2 
compared  controls (Figure 8A and 8B). Less SOCS3 expression is observed in 
Ba/F3-FLT3-ITD cells  than the control  Ba/F3 cells (Figure 8B). These results 
indicate that FLT3-ITD leads  to the expression of SOCS genes in myeloid and 
lymphoid cell lines, confirming our previous microarray results. 
4.2.2  SOCS1 expression was highly induced by FLT3-ITD in murine bone 
marrow 
 
Figure 9: Retroviral expression of FLT3-ITD in murine bone marrow stem/ progenitor cells 
induced very high expression of SOCS1 and moderate expression of CIS, SOCS2 and 
SOCS3. Murine bone marrow stem and progenitor cells were transduced with FLT3-ITD or an empty 
GFP vector (control) and sorted for GFP. Cells were starved overnight of cytokine cocktail. The 
expression of CIS, SOCS1-3 transcripts was  measured by quantitative PCR as described in 
methods section. Normalized gene expression is plotted with standard deviations as error bars. (* 
p<0.05, ** p<0.01) 
Next, SOCS gene expression by FLT3-ITD in primary murine bone marrow was 
analyzed. For this purpose, bone marrow enriched for stem / progenitor cells (5-FU 
treated) was transduced with either control or with FLT3-ITD and compared the 
relative mRNA expression of SOCS genes was compared by RT-PCR. As shown in 
Figure 9, FLT3-ITD expression led to very high induction of SOCS1 (59 fold) and a 
moderate induction of CIS (2.3 fold), SOCS2 (2 fold) and SOCS3 (3.2 fold) mRNA 
expression compared to control. Further substantiating these RT-PCR results, 
SOCS1 protein can be detected in primary murine bone marrow by FLT3-ITD     Results 
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(Figure 9B). These results clearly demonstrate SOCS1 to be the most regulated 
SOCS gene by FLT3-ITD in bone marrow stem / progenitor cells. 
4.3  Kinase dependent expression of SOCS genes in FLT3-ITD
+ AML 
derived cell lines 
After SOCS gene expression in cell lines and in primary bone marrow stem cells by 
FLT3-ITD  was observed, the requirement of FLT3-ITD kinase activity for the 
induction of SOCS genes were determined. 
 
 
Figure  10:  FLT3-ITD kinase activity is required for CIS, SOCS1-3 mRNA expression and 
SOCS1 protein expression in AML patient-derived cell lines. 
Real time quantitative PCR analysis of CIS, SOCS1-3 mRNA expression in (A) MV4-11 and (B) 
MOLM-13 cell lines. MV4-11 and MOLM-13 cells were incubated overnight with the FLT3 kinase 
inhibitor PKC412 (100 ηM) or with solvent control (DMSO) as indicated. Normalized RNA 
expression is plotted with standard deviation as error bars. (C) Endogenous SOCS1 protein is 
decreased upon kinase inhibition. Western blot analysis of MOLM-13 cells either treated with 
PKC412 (100 ηM) or with DMSO. Actin blot served as protein loading control. (* p<0.05, ** p<0.01)  
To test this, two AML-derived FLT3-ITD positive cell lines MV4-11 and MOLM-13 
were cultured overnight with or without PKC412 (a FLT3 specific kinase inhibitor) 
and relative mRNA levels of SOCS members were measured. Both MV4-11 and     Results 
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MOLM-13 cell lines showed decreased CIS, SOCS1, SOCS2 and SOCS3 
expression upon FLT3 inhibition with PKC412 (Figure 10A and 10B). In agreement 
with RT-PCR results, in MOLM-13 cells, SOCS1 protein expression is decreased to 
an undetectable level upon PKC412 treatment (Figure 10C).  In MV4-11 and in 32D 
cells over expressing FLT3-ITD, SOCS1 expression could not be detected on 
protein level (data not shown).   
4.4  SOCS1 is highly expressed in FLT3-ITD
+ AML patient bone marrow 
As SOCS1 expression is highly up-regulated by FLT3-ITD in primary murine bone 
marrow and in AML derived FLT3-ITD positive cell lines next, SOCS1 and SOCS3 
expression in bone marrow samples from AML patients is determined. SOCS1, but 
not SOCS3 was significantly highly induced in FLT3-ITD positive AML patient bone 
marrow compared to CD34 positive healthy bone marrow samples (Figure 11A and 
11B).  
 
Figure 11: SOCS1 and SOCS3 mRNA is highly expressed in AML patient bone marrow. Bone 
marrow samples from a cohort of 77 AML patients (38 of FLT3-ITD and 39 FLT3-WT) and 7 healthy 
CD34+ donors were analyzed for the expression of (A) SOCS1 and (B) SOCS3. The normalized 
mRNA expression is plotted with standard errors as error bars. (* p<0.05)  
Taken together, SOCS genes are induced by FLT3-ITD in a kinase dependent 
manner in cell lines and murine bone marrow. Particularly SOCS1 mRNA and 
protein were highly up-regulated by FLT3-ITD in murine bone marrow stem cells 
and finally, very importantly SOCS1 mRNA was expressed significantly high in 
FLT3-ITD positive AML-patient bone marrow.      Results 
 
 
  41 
4.5  Role of SOCS1 in FLT3-ITD mediated transformation in vitro   
Various reports have shown that SOCS1 could block the oncogenicity of several 
hematopoietic specific oncogenes like the constitutively active form of the KIT 
receptor, TEL-JAK2, v-ABL, oncogenic form of VAV and partially BCR/ABL  (De 
Sepulveda et al., 2000; Rottapel et al., 2002).  Given the tumor suppressor nature 
of SOCS1, its role was systematically studied in FLT3-ITD mediated transformation 
in vitro and in vivo.  
4.5.1  SOCS1 co-expression with FLT3-ITD 
Given the tumor suppressor nature of SOCS1, it is  expected  that SOCS1 co-
expression might block or reduce the oncogenicity of FLT3-ITD. As described in 
materials and methods, a retroviral vector with IRES driven GFP expression that 
simultaneously expresses SOCS1 and FLT3-ITD was made and it enables tracking 
and isolation of cells.  
4.5.2  SOCS1 co-expression did not affect FLT3-ITD mediated signaling 
pathways 
32D cells retrovirally transduced with SOCS1-T2A-FLT3-ITD indeed have SOCS1 
and FLT3 protein  expression.  Completely  cleaved, well separated FLT3 and 
SOCS1 as shown by western blot at their respective molecular weights and that 
amount FLT3 expression was equal to the expression of FLT3 in 32D cells 
expressing FLT3-ITD alone (Figure 12). Two bulk cultures of SOCS1-T2A-FLT3-
ITD were used to avoid the possibility of clonal selection. SOCS1 co-expression 
does not affect the auto-phosphorylation of FLT3-ITD, PI3K/Akt, MAPK/ERK, and 
STAT5 pathways as evidenced by similar phosphorylation levels of FLT3, Akt, ERK 
and STAT5 compared to FLT3-ITD alone (Figure 12).     Results 
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Figure 12: SOCS1 co-expression does not inhibit FLT3-ITD activated signaling. Western blot 
analysis of retrovirally transduced stable 32D cells expressing FLT3-ITD or SOCS1-T2A-FLT3-ITD 
or control (empty vector). Cells were washed 3 times with sterile PBS and cultured overnight in 0.5% 
FCS and lysates were made. Equal amounts of total cell lysates were resolved by SDS-PAGE and 
blotted on to PVDF membranes. These membranes were incubated with indicated phospho-specific 
antibodies that represent activation of a particular  pathway. Subsequently, membranes were 
reprobed for the total antibodies and actin to ensure equal loading. Two independent bulk cultures (1 
and 2) of SOCS1-T2A-FLT3-ITD were used to exclude clonal artifacts. 
 
Equal  levels  of  Pim1  and Pim2 proteins (STAT5 targets)  in both FLT3-ITD and 
SOCS1-T2A-FLT3-ITD could also be observed.  This experiment clearly indicates 
that SOCS1 could not affect any major FLT3-ITD mediated signaling pathways. 
4.5.3  SOCS1 co-expression did not affect FLT3-ITD mediated proliferation 
but abrogated IL-3 mediated proliferation and protected from Interferon 
mediated growth inhibition 
Next the functional  consequences of  SOCS1 co-expression  on  (i)  FLT3-ITD 
mediated proliferation, (ii) IL-3 mediated proliferation, (iii) IFNα / IFNγ  mediated 
growth inhibition, (iv) IFNα and IFNγ signaling were analyzed. 
DNA synthesis was  measured by 3[H]-thimidine incorporation in 32D cells 
expressing FLT3-ITD, SOCS1-T2A-FLT3-ITD and GFP control, in the presence or 
absence of IL-3, IFNα, IFNγ and PKC412 (a FLT3 specific tyrosine kinase inhibitor). 
As shown in Figure 13A, SOCS1 did not inhibit FLT3-ITD mediated DNA synthesis.     Results 
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As expected, when FLT3-ITD kinase activity (PKC412) is inhibited, co-expression 
of SOCS1 severely impaired IL-3-induced proliferation of 32D cells (Figure 13A). 
Importantly, when cells were cultured with growth inhibitory cytokines (IFNα and 
IFNγ), SOCS1 co-expression led to increased proliferation (Figure 13A), indicating 
that  SOCS1 expression could protect FLT3-ITD cells from growth inhibitory 
cytokines while not altering FLT3-ITD mediated proliferation. 
In a competitive proliferation assay, retroviral transductions with GFP control, 
SOCS1, FLT3-ITD and SOCS1-T2A-FLT3-ITD were performed and compared the 
percentage of GFP-positive (i.e. transduced) versus GFP-negative (non-
transduced) cells in the absence of IL-3 (Figure 13B) and in the presence of IL-3 
(Figure 13C). In the absence of IL-3, the control and the SOCS1 transduced 32D 
cells rapidly died (undetectable GFP expression) (Figure 6B), 32D cells transduced 
with  FLT3-ITD or SOCS1-T2A-FLT3-ITD grew out to a homogeneous GFP
+ 
population at a similar rate. This demonstrated that SOCS1 co-expression has no 
influence on FLT3-ITD induced cell proliferation (Figure 13B). In the presence of IL-
3, 32D cells expressing SOCS1 rapidly died,  leaving no  detectable GFP+ cells 
(Figure 13C). In contrast, the percentage of GFP-positivity remained constant in 
GFP control, FLT3-ITD, SOCS1-T2A-FLT3-ITD transduced cells (Figure 13C). This 
implies that although SOCS1 expression inhibited IL-3 dependent proliferation of 
32D cells, the FLT3-ITD dependent proliferation was resistant to SOCS1 inhibition. 
Taken together these experiments in 32D cell line  show that FLT3-ITD induced 
SOCS1 could not affect FLT3-ITD activated signaling and proliferation, while 
abolishing the IL-3 induced proliferation and protecting from Interferons (IFNα and 
IFNγ) mediated growth inhibition. 
     Results 
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Figure 13: Biological consequences of SOCS1 co-expression with FLT3-ITD. (A) Proliferation 
assay by measurement of DNA synthesis using 
3[H]-thymidine incorporation. The stable 32D cells 
expressing the indicated constructs were analyzed for their proliferation by 
3[H]-thymidine 
incorporation as described in materials and methods. The data is plotted as a graph with the mean 
of quadruplicates and standard deviation as error bars. (B and C) Competitive proliferation assays of 
32D cell lines expressing control (GFP), SOCS1, FLT3-ITD and SOCS1-T2A-FLT3-ITD. One day 
after retroviral transduction, 32D cells were washed 3 times with PBS and cultured without IL-3 (B) 
or with IL-3  (C) and the percentage of GFP is measured by FACS at 24 hours intervals. The 
percentage of GFP is plotted with standard deviation as error bars. (* p<0.05) 
4.5.4  Interferon alpha and Interferon gamma induced STAT1 activation is 
diminished by FLT3-ITD 
Implication of increased SOCS1 expression by FLT3-ITD on IFNα  and IFNγ 
mediated STAT1 activation, which is a key mediator of anti-proliferative function 
downstream of IFNα and IFNγ receptors was studied.  32D cells expressing either     Results 
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GFP control or FLT3-ITD or SOCS1-T2A-FLT3-ITD, were examined for STAT1 
phosphorylation after IFNα or IFNγ stimulation. In response to IFNα and IFNγ, cells 
expressing  FLT3-ITD showed less STAT1 phosphorylation compared to control, 
which was further diminished by SOCS1 co-expression (SOCS1-T2A-FLT3-ITD) 
(Figure 14). 
 
Figure 14: IFNα and IFNγ mediated STAT1 activation is diminished in 32D-FLT3-ITD cells, 
possibly due to FLT3-ITD induced SOCS1 expression. 32D cells expressing empty vector 
(control), FLT3-ITD or SOCS1-T2A-FLT3-ITD were either stimulated with IFNα (1000 U/mL) and 
IFNγ (100 ng/mL) for 10 minutes or left unstimulated. Equal amounts of protein is resolved on SDS-
PAGE then blotted on to PVDF membrane. STAT1 activation is measured as indicated with 
phospho-specific STAT1 antibody, actin is the loading control. 
4.5.5  SOCS1 co-expression with FLT3-ITD protected primary bone marrow 
from Interferon gamma  
Experiments with 32D cells hinted that SOCS1 co-expression leads to inhibition of 
external cytokine cues, hence the implication of SOCS1 induction/co-expression, 
on growth inhibitory cytokines were analyzed in a more biologically meaningful 
setting (i.e. murine bone marrow stem and progenitor cells). 
Stem and progenitor cell enriched (5-FU treated) bone marrow was retrovirally 
transduced with GFP control, SOCS1, FLT3-ITD, and SOCS1-T2A-FLT3-ITD then 
isolated for GFP by FACS. First, the relative expression of SOCS1 mRNA in the 
GFP sorted bone marrow stem and progenitors cells was checked. As shown in 
Figure 15A, a comparable amount of SOCS1 mRNA is expressed in both SOCS1 
and FLT3-ITD transduced bone marrow stem progenitors. And SOCS1-T2A-FLT3-
ITD had about 5-fold higher SOCS1 mRNA expression compared to FLT3-ITD 
(Figure  15A).  Next,  FLT3 and SOCS1 protein expression was analyzed in GFP 
sorted bone marrow progenitors. As shown in Figure 15B, amount of FLT3 protein     Results 
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expression in both FLT3-ITD and SOCS1-T2A-FLT3-ITD was equal. FLT3-ITD 
induced SOCS1 protein (running at a slightly lower  molecular weight) and 
retrovirally co-expressed SOCS1 protein (running at a slightly higher molecular 
weight, due to the  extra amino acids from the  T2A peptide cleave) could be 
detected by western blot. This indicates endogenous SOCS1 induced by FLT3-ITD 
is much less in amount compared to that of exogenously expressed SOCS1. 
Although the level of SOCS1 mRNA expression in FLT3-ITD transduced bone 
marrow and SOCS1 transduced bone marrow is equal, SOCS1 protein can be 
detected only in FLT3-ITD bone marrow by western blot.  
The above-mentioned bone marrow cells were measured for their clonogenic 
growth. Colony forming assays were performed in methylcellulose containing pro-
proliferative cytokines (IL-3, IL-6, SCF) and in anti-proliferative cytokine (IFNγ). As 
indicated in Figure 15C (left panel), colony growth was severely impaired in bone 
marrow expressing SOCS1 in methylcellulose containing IL-3, IL-6 and SCF, but 
this was reversed with FLT3-ITD co-expression, once again ascertaining FLT3-ITD 
resistance to inhibitory effects SOCS1 in bone marrow stem cells. Of note, both 
FLT3-ITD and SOCS-T2A-FLT3-ITD made comparable number of colonies.  
However, in the presence of IFNγ, an anti-proliferative cytokine, SOCS1-T2A-FLT3-
ITD made significantly higher numbers of colonies compared to FLT3-ITD (Figure 
15C, right panel). This is because of the higher expression of exogenous SOCS1 in 
SOCS1-T2A-FLT3-ITD, which led to efficient protection from growth inhibitory 
function of IFNγ compared to the relative small amount of endogenous SOCS1, 
which is induced by FLT3-ITD. SOCS1 is known to inhibit IFNγ by inhibiting JAK 
kinases downstream of IFNγ  receptor  (Endo et al., 1997; Fenner et al., 2006).  
Neither GFP control nor SOCS1 could form colonies.     Results 
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Figure 15: SOCS1 co-expression with FLT3-ITD in murine bone marrow stem/ progenitor cells 
conferred resistance to IFNγ inhibitory effects. Murine bone marrow Stem / progenitor cells were 
transduced with empty GFP vector (control), SOCS1, FLT3-ITD and SOCS1-T2A-FLT3-ITD and 
sorted for GFP. These cells were starved of cytokine cocktail and FCS overnight, then (A) SOCS1 
mRNA expression and (B) FLT3, SOCS1 and GFP protein expression were measured by 
quantitative PCR and western blot respectively. Actin, GFP blots ensure equal protein loading. (C) 
Sorted GFP cells were washed three times with PBS and plated at a density of 2000 cells/mL in 
triplicates in either methylcellulose medium containing IL-3, SCF, IL-6 or in methylcellulose medium 
containing IFNγ. Colony numbers were counted after 12 days and mean colony number from 
triplicates was plotted with standard deviation as error bars. (D) Serial replating of colony assays in 
methylcellulose containing IL-3, SCF and IL-6. (* p<0.05) 
Taken together these data show that  FLT3-ITD induced SOCS1 expression in 
primary bone marrow protected cells from external growth inhibitory cytokines 
(IFNγ). 
Although it was shown that FLT3-ITD does not increase replating activity of primary 
bone marrow (Li et al., 2008)), it was tested whether SOCS1 co-expression could 
alter this phenomenon. A similar replating efficiency of SOCS1-T2A-FLT3-ITD as     Results 
 
  48 
FLT3-ITD was observed, suggesting that SOCS1 does not influence the replating 
capacity of FLT3-ITD (Figure 15D). 
4.6  Role of SOCS1 expression in FLT3-ITD induced leukemogenesis in 
vivo 
FLT3-ITD has been shown to induce a myeloproliferative disease in a murine bone 
marrow transplantation model (Grundler et al., 2005; Kelly et al., 2002b) and either 
a myeloproliferative or lymphoid disease in a transgenic mouse model (Lee et al., 
2005; Li et al., 2008).  The role of SOCS1 in FLT3-ITD mediated leukemogenesis is 
studied in a murine bone marrow transplantation model.  
4.6.1  SOCS1 co-expression enhanced FLT3-ITD bone marrow engraftment 
and proliferation 
Bone marrow transduction and transplantations were done as described in the 
materials and methods section. 5-FU treated bone marrow stem and progenitor 
cells were transduced retrovirally with GFP control, SOCS1, FLT3-ITD and SOCS1-
T2A-FLT3-ITD. The transduced bone marrow cells were transplantated into lethally 
irradiated recipient mice. After the transplantation, peripheral blood parameters of 
all animals were monitored for the engraftment and for the development of leukemic 
symptoms at a regular interval of 10-days. If mice fail to engraft the transplants they 
will die shortly after transplantation, but none of the animal were dead immediately 
after transplantation indicating successful bone marrow transplantation. 
As shown in Figure 16A, the percentage of GFP expressing cells in the peripheral 
blood from control mice remained constant over a period of 30 days, while there 
were no detectable GFP expressing cells present in SOCS1 transplanted mice by 
20 days. This clearly demonstrates a competitive growth disadvantage of SOCS1 
transplants in the latter group. On the other hand, the percentage of GFP positive 
cells in FLT3-ITD or SOCS1-T2A-FLT3-ITD transplanted mice were significantly 
increased from day 10 to day 30, with an increase of 9.3% to 54% and 13.9% to 
67.3% respectively (p<0.05, Figure 16A).  
Similarly, WBC counts of FLT3-ITD mice (3.3 x 10
3/µL on day 10 to 4.3 x 10
4/µL on 
day 30) and SOCS1-T2A-FLT3-ITD mice (1.2 x 10
3/µL on day 10 to 4.8 x 10
4/µL on 
day 30) showed a significant increase compared to control mice (p<0.05, Figure 
16B). Both the increase of GFP positive cells and WBC in the FLT3-ITD and the     Results 
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SOCS1-T2A-FLT3-ITD mice indicate a competitive growth advantage of these 
cells. These mice also show signs of leukemia such as lower hemoglobin content 
and PLT count when compared to the control or SOCS1  (Figure 16C and 16D).  
 
 
Figure  16:  Post-transplantation follow-up of mice for engraftment and development of 
leukemia. Bone marrow transduction and transplantation was performed as described in methods 
section. All transplanted mice were bled at  10-day intervals. The peripheral blood cell counts (WBC, 
platelet, and hemoglobin content) were measured by Haemavet and GFP expression was measured 
by flow cytometry. The mean values from each different group of mice were plotted as (A) 
percentage GFP, (B) WBC count (x 1000/µL), (C) Hemoglobin content (g/dL) and (D) Platelets count 
(x 1000/µL) versus time in days of post transplantation.  
 
In agreement with the post-transplantation follow-up, the percentage of GFP 
expressing cells in the control mice at the end of the experiment (day 120) was 
comparable to the percentage of GFP at day 10, and there was no detectable GFP 
in SOCS1 mice at day 120 (Table1). Similarly both FLT3-ITD and SOCS1-T2A-
FLT3-ITD mice had high percentages of GFP+ cells and higher WBC counts at the 
time of death. Detailed analysis of peripheral blood from control, SOCS1 mice (after     Results 
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120 days) and FLT3-ITD, SOCS1-T2A-FLT3-ITD mice (at the time of death) are 
given in Table 2. 
4.6.2  SOCS1 co-expression accelerated the onset of FLT3-ITD induced 
myeloproliferative disease and acute lymphoblastic leukemia 
 
 
 
Figure 17: SOCS1 accelerates FLT3-ITD induced disease onset in murine bone marrow 
transplant model.  Kaplan-Meyer plot displaying survival post transplantation, no mice received 
transplant of control or SOCS1 died during the experiment. The mean survival of mice transplanted 
with FLT3-ITD was 56d ± 21d; with SOCS1-T2A-FLT3-ITD was 34d ± 9.6d (p = 0.01). All animals 
from FLT3-ITD and SOCS1-T2A-FLT3-ITD died before the end of the experiment. 
 
Importantly, none of control mice or SOCS1 mice developed a disease phenotype 
until the end of the experiment (i.e. 120 days). All the mice transplanted with FLT3-
ITD and SOCS1-T2A-FLT3-ITD developed either a myeloproliferative disease 
(MPD) or an acute lymphoblastic leukemia (B-ALL) with 100% penetration. Mice 
which received a FLT3-ITD transplant died with a median survival of 48.5 days 
(range 36-83) and those which received a SOCS1-T2A-FLT3-ITD transplant died 
with a median survival of 32.5 days (range 22-56). Three of 6 FLT3-ITD mice 
developed MPD (72.5% of Gr1+ peripheral blood cells) and 3 out of 6 developed B-
ALL (96.4% of CD19+  peripheral blood cells) (Table 2). Similarly,  5 out of 10     Results 
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SOCS1-T2A-FLT3-ITD mice developed MPD (64% of Gr1+ peripheral blood cells) 
and 5 out of 10 developed B-ALL (85.4% CD19+ peripheral blood cells) (Table 2). 
Although SOCS1 co-expression did not alter the disease phenotype, it significantly 
accelerated the disease development (p = 0.01, Figure 17). 
 
     
  
No. 
mice 
(n) 
Phenotype  WBC (10
3/ µL)  Hb (g/dL)  PLT (10
3/ 
µL)  % GFP
+  % CD19
+  % GR1
+ 
Control  7  none  6.9  
(4.6-11.2) 
16  
(11.4-17.5) 
499  
(335-1203) 
5  
(0.9-6.1) 
11.2  
(7.4- 23.7) 
22.1  
(11.8-26.7) 
SOCS1  10  none  6.2  
(4.5-16.6) 
14.9  
(12.9-16.9) 
256  
(131-2612) 
0.7  
(0-2.2) 
9.7  
(0.5-21.6) 
27.8  
(19.3-40.1) 
FLT3-ITD  6 
3 MPD  36.8  
(36.8-42.1) 
12  
(9.6-14.3) 
574  
(497-651) 
48.1  
(9.2-87.1) 
3.4  
(1.1-4.8) 
72.5  
(45.4-88.8) 
3 ALL  86.1  
(47.5-86.1) 
14  
(11.0-16.6) 
441  
(282-466) 
75  
(39.3-87.8) 
96.4  
(23.0-97.4) 
1.2  
(0.2-54.8) 
SOCS1-
T2A-
FLT3-ITD 
10 
5 MPD  34.5  
(11.1-61.9) 
14.6  
(10.4-17.3) 
321  
(227-539) 
73.6  
(61.2-90.7) 
5.9  
(2.3-19.9) 
64  
(60.7-90.2) 
5 ALL  16.8  
(3.4-76.0) 
15.8  
(13.7-17.0) 
365  
(312-463) 
83.3  
(21.6-97.6) 
85.4  
(77.2-93.6) 
5  
(3.1-7.1) 
 
Table 2: Peripheral blood analysis of transplanted mice at the time of death.  
Mice transplanted with bone marrow expressing FLT3-ITD or SOCS1-T2A-FLT3-ITD were sacrificed 
when moribund, while mice transplanted with bone marrow expressing control GFP or SOCS1 were 
sacrificed at the end of the experiment at day 120. Peripheral blood analysis included white blood 
cell count (WBC), hemoglobin content (Hb), platelets (PLT), the % of GFP expression and surface 
expression of lineage specific markers CD19 (immature B cell) and Gr1 (granulocytes). MPD: 
myeloproliferative disease; ALL: acute lymphoblastic leukemia. Values are presented as median 
(range). 
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Table 3: Bone marrow and splenocyte analysis of transplanted mice at the time of death. Mice 
transplanted with bone marrow expressing FLT3-ITD or SOCS1-T2A-FLT3-ITD were sacrificed 
when moribund, while mice transplanted with bone marrow expressing control GFP or SOCS1 were 
sacrificed at the end of the experiment at day 120. Bone marrow and spleen cells were analyzed for 
GFP positivity to monitor infiltration of transplants and for surface expression of lineage specific 
markers CD19 (immature B cells), GR1 (granulocytes) CD117 (KIT receptor). MPD: 
myeloproliferative disease; ALL: acute lymphoblastic leukemia. Values are presented as median 
(range). 
4.6.3  Spleen, liver and bone marrow infiltration in FLT3-ITD or SOCS1-T2A-
FLT3-ITD transplanted mice  
All moribund mice transplanted with either FLT3-ITD or SOCS1-T2A-FLT3-ITD 
showed enlarged spleens (Figure 18A). Spleen weights of FLT3-ITD and SOCS1-
T2A-FLT3-ITD were significantly higher compared to control mice (Figure 18B). 
Similarly, a significant increase in liver weights in the SOCS1- T2A-FLT3-ITD mice 
compared to control mice was observed, whereas the FLT3-ITD mice had slightly 
enlarged livers which were not statistically significant (Figure 18C). FLT3-ITD and 
SOCS1-T2A-FLT3-ITD transplanted mice showed higher WBC or nucleated cells in 
their peripheral blood (blood smears), compared to SOCS1 and control mice 
(Figure 19A and Table 2). 
Leukemia progression is marked by the infiltration of blasts in various organs and 
therefore  sacrificed moribund mice were  assessed for these signs by making 
histopathological sections of fixed organs and immunostaining followed by 
microscopy. Histological examination of spleens and livers from FLT3-ITD and 
SOCS1-T2A-FLT3-ITD demonstrate blast infiltrations and destruction of the natural 
 
  
No. 
analyzed, 
Phenotype 
Bone marrow  Splenocytes 
      % GFP
+  % CD19
+  % GR1
+  % 
CD117
+  % GFP
+  % CD19
+  % GR1
+  % 
CD117
+ 
Control  7, no 
phenotype 
1.4  
(0.7-6.7) 
19.9  
(7.7-27.2) 
66.8  
(41.6-82.1) 
12.8  
(4.0-22.6) 
2.3  
(0.8-11.4) 
42.6  
(23.6-53.0) 
18.7  
(8.8-24.2) 
4.4  
(1.1-9.1) 
SOCS1  10, no 
phenotype  
0.3  
(0.0-1.4) 
33.4  
(12.1-
43.1) 
58.5  
(40.6-85.3) 
7.2  
(0.3-18.5) 
0.3  
(0.0-1.4) 
56.2  
(24.1-61.4) 
11.4  
(1.4-25.9) 
3.2  
(0.2-4.3) 
FLT3-ITD 
2, MPD  34.5  
(21.8-47.1) 
27.2  
(8.2-46.3) 
53.8  
(41.1-66.4)  6.2  53.1  
(45.4-60.7) 
13.6  
(1.9-25.2) 
50.2  
(33.7-66.7)  7.4 
2, ALL  63.6  
(36.6-90.6) 
83  
(69.7-
96.2) 
1.6  
(1.3-1.8) 
0.8  
(0.2-1.5) 
53.7  
(26.1-81.2) 
44.8  
(13.3-76.3) 
4.7  
(2.4-6.9) 
5.3  
(3.1-7.5) 
SOCS1-
T2A- 
FLT3-ITD 
1, MPD  22.6  5.1  56.2  2.5  47.8  2.6  39.0  2.6 
4, ALL  81.8  
(43.8-96.0) 
89.2  
(74.6-
97.2) 
 9.6  
(6.7-19.3)  
 1.2  
(0.2-3.8)  
90  
(83.0-93.4) 
90.6  
(87.4-92.1) 
6.7  
(5.4-7.5) 
4  
(2.5-6.0)     Results 
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organ architecture (Figure 19B). Furthermore, there was a clear increase in bone 
marrow cellularity in both groups of mice compared to controls, with a loss of bone 
marrow adipocytes (Figure 19B). The detailed FACS analysis of spleen, bone 
marrow infiltrates is  shown in Table 3. All the mice from both FLT3-ITD and 
SOCS1-T2A-FLT3-ITD, which suffered from MPD, exhibited  spleen and bone 
marrow infiltrated with Gr1/GFP positive cells. Similarly those mice which suffered 
from B-ALL, had spleen and bone marrow infiltrated with CD19/GFP positive cells 
(Table 3). 
 
Figure 18: Mice transplanted with  FLT3-ITD and SOCS1-T2A-FLT3-ITD displayed enlarged 
spleen and liver.  (A) Representative spleens from control, SOCS1 groups (120d post-
transplantation) and from moribund mice of FLT3-ITD and SOCS1-T2A-FLT3-ITD groups, indicating 
normal or enlarged spleens, respectively. Analysis of spleen weights (B) and liver weights (C) at the 
time of death or at the end of experiment (120d).  Mice received transplant of  FLT3-ITD  and 
SOCS1-T2A-FLT3-ITD have enlarged spleens compared to control.  (* p<0.05, ** p<0.01, 
***p<0.001) 
     Results 
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Figure 19: Histology of transplanted mice. (A) Representative bone marrow smears from 120d 
post-transplantation control and SOCS1 or from FLT3-ITD and SOCS1-T2A-FLT3-ITD  moribund 
mice, indicating a normal or high number of immature myeloid / lymphoid blasts respectively.(B) 
Hematoxylin and eosin staining (H&E) of tissues (spleen, liver) from control and SOCS1 mice and 
leukemic FLT3-ITD and SOCS1-T2A-FLT3-ITD mice. Data are representative of one of 6 moribund 
FLT3-ITD animals and one of 10 moribund SOCS1-T2A-FLT3-ITD mice.     Results 
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4.6.4  SOCS1 co-operates with MPD development  
Interestingly,  when  survival was analyzed with respect to the phenotype and 
latency, a surprising correlation was observed: SOCS1 co-expression significantly 
shortened the latency of FLT3-ITD induced myeloproliferative disease phenotype (p 
= 0.01, Figure 19 left panel), while the latency of FLT3-ITD induced B-cell acute 
lymphoblastic leukemia disease phenotype was not affected (p = 0.85, Figure 19 
right panel). This clearly shows that SOCS1 co-expression with FLT3-ITD 
accelerates the myeloproliferative disease but not acute lymphoblastic leukemia 
(Figure 20A). 
4.6.5  Model for SOCS1 co-operation with FLT3-ITD 
Together these data provide  a  model  in which mutant FLT3-ITD up-regulates 
SOCS family proteins particularly SOCS1 which inhibits pro and anti-proliferative as 
well as differentiation signals from cytokines. By abrogating these external signals, 
cells expressing FLT3-ITD are under the dictate of pro-proliferative and survival 
signals transmitted downstream of the oncogenic receptor. This model may explain 
`SOCS paradox`, the seemingly contradictory finding of increased expression of 
SOCS1 with tumor suppressor function, in context of oncogenic kinase FLT3-ITD 
(Figure 20B). 
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Figure 20: SOCS1 play important role in FLT3-ITD mediated myeloproliferative disease. 
(A) Comparison of median survival of mice developed MPD (FLT3-ITD = 82d ± 18.8d, SOCS1-T2A-
FLT3-ITD = 30d ± 4.8d) and ALL (FLT3-ITD = 39d ± 5.7d, SOCS1-T2A-FLT3-ITD = 35d ± 10.3d). 
On the Y-axis the median survival (in days +/- standard deviation) is plotted, and separately shown 
for MPD and ALL phenotype.  (B) Mechanistic model for  co-operation of SOCS1 in FLT3-ITD 
mediated leukemogenesis.  Constitutively active oncogenic FLT3-ITD directly  phosphorylates 
STAT5. Upon phosphorylation STAT5 dimerizes and translocates into nucleus and induces 
transcription of STAT5 target genes, which includes SOCS1. FLT3-ITD induced SOCS1 expression 
neither affects FLT3-ITD mediated proliferative signals nor the STAT5 activation, while it terminates 
cytokine. Thereby, SOCS proteins cooperate with FLT3-ITD by “shielding” the cell from cytokine 
control (for example IFNα, IFNγ, IL-3 and IL-6). 
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4.7  Role of SOCS proteins in BCR/ABL mediated leukemogenesis 
4.8  SOCS gene expression in patient derived ALL cells 
4.8.1  CIS, SOCS2, SOCS3 were highly expressed in BCR/ABL positive, long-
term cultures of primary acute lymphoblastic leukemia patient samples 
BCR/ABL  is an oncogenic fusion protein associated with acute lymphoblastic 
leukemia  and chronic myeloid  leukemia.  BCR/ABL  also highly activates STAT5 
similar to FLT3-ITD and additionally STAT3. SOCS genes are known STAT3 and 
STAT5 target genes. Since it was already observed that SOCS1 and SOCS3 are 
highly expressed in AML patient bone marrow, their expression was analyzed in 
long-term cultures of primary cells from patients with acute lymphoblastic leukemia.  
Quantitative real-time PCR results show high CIS, SOCS2 and SOCS3 expression 
in BCR/ABL positive patient cell lines compared to BCR/ABL negative patient cell 
lines. Although SOCS4, SOCS5, SOCS6 and SOCS7 mRNA was detected in ALL 
patient cell lines, their expression was independent of the presence or absence of 
BCR/ABL (Figure 21). Surprisingly, a high SOCS1 expression in BCR/ABL negative 
cell lines was observed (Figure 21). 
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Figure 21: CIS, SOCS2 and SOCS3 are highly expressed in BCR/ABL positive ALL patient cell 
lines. Long-term cultures cell lines from BCR/ABL positive patients (BV, CM, WD, KW, PH and VB) 
and BCR/ABL negative patients (VG, KR, RL, SK, CR and HP) were analyzed for CIS, SOCS1-
SOCS7 mRNA expression by real time quantitative PCR as described in methods section. 
Normalized SOCS gene expression of BCR/ABL positive cell lines is plotted comparing to BCR/ABL 
negative cell lines (standard deviations as error bars).      Results 
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4.8.2  CIS, SOCS2 and SOCS3 expression is Abl kinase dependent in long-
term cultures of primary acute lymphoblastic leukemia patient samples 
The observed high CIS, SOCS2, SOCS3 expression in BCR/ABL positive ALL cell 
lines was further tested to determine Abl kinase dependence. For this purpose, 
BCR/ABL positive cell lines were treated overnight with Abl specific kinase inhibitor 
imatinib (1 µM) followed by SOCS gene expression as measured by quantitative 
PCR. Solvent treated cell lines were used as a control. As shown in Figure 22, Abl 
inhibition led to decreased expression of CIS, SOCS2 and SOCS3 mRNA in all cell 
lines, whereas Abl inhibition had varying effects on SOCS1 expression in different 
cell lines. As expected SOCS4, SOCS5, SOCS6 and SOCS7 expression was not 
influenced by the inhibition of Abl (Figure 22). 
 
Figure 22: Kinase dependent expression of CIS, SOCS2 and SOCS3 in BCR/ABL positive ALL 
patient cell lines. Long-term cultured cell lines from BCR/ABL positive patients (BV, CM, WD, KW, 
PH and VB) were treated overnight with 1 µM imatinib (Abl specific kinase inhibitor) or with solvent 
control and   CIS, SOCS1-SOCS7 mRNA expression is analyzed by real time quantitative PCR as 
described in the methods section. Normalized SOCS gene expression of imatinib treated cell lines is 
plotted with standard deviations as error bars. 
4.9  Kinase dependent expression of CIS, SOCS1 and SOCS3 in K-562 
cell line  
SOCS gene expression was tested in the K-562 cell line, which is used extensively 
to study BCR/ABL  signaling pathways.  K-562 cells were treated overnight with 
either Abl kinase inhibitor imatinib (2 µM) or with a solvent control, SOCS mRNA 
expression was measured by quantitative PCR. As shown in Figure 23, CIS, 
SOCS1 and SOCS3 mRNA is highly expressed in K-562 cells and their expression     Results 
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is diminished with Abl kinase inhibition. SOCS4, SOCS5, SOCS6 and SOCS7 
expression is very low and their expression is not affected by Abl inhibition. 
 
Figure 23:  Kinase dependent expression of CIS, SOCS2 and SOCS3 in K-562 cell line. K-562 
cells were treated overnight with 2 µM imatinib (Abl specific kinase inhibitor) or with solvent control 
and CIS, SOCS1-SOCS7 mRNA expression is analyzed by real time quantitative PCR as described 
in the methods section. Normalized SOCS gene expression of imatinib treated cell lines is plotted in 
comparison to solvent control treated cell lines (standard deviations as error bars).  
4.10 Ectopic expression of BCR/ABL in murine bone marrow induced 
SOCS gene expression 
 
Figure 24: BCR/ABL induces SOCS gene expression in murine bone marrow. Murine bone 
marrow stem and progenitor cells were transduced with BCR/ABL or an empty GFP vector (control) 
and sorted for GFP. Cells were starved overnight of cytokine cocktail. The  expression of CIS, 
SOCS1-3 transcripts was  measured by quantitative PCR as described in methods section. 
Normalized gene expression is plotted with standard deviations as error bars.     Results 
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Next, SOCS gene expression by BCR/ABL in primary murine bone marrow was 
analyzed.  Lineage depleted bone marrow cells expressing either control or 
BCR/ABL were starved from serum and cytokines and SOCS gene expression was 
measured by quantitative PCR.  As shown in Figure 24, BCR/ABL expressing bone 
marrow cells have higher CIS, SOCS1-3 expression compared to control. 
4.11 SOCS1 did not affect BCR/ABL mediated proliferation, while 
abrogating IL-3 mediated proliferation  
SOCS1 is expressed in a kinase dependent manner in K-562 cell line, and three of 
6 BCR/ABL positive ALL cells.  The  consequence of SOCS1 co-expression with 
BCR/ABL in a Ba/F3 cell line (a pro-B cell line) was tested. Ba/F3 cells expressing 
either BCR/ABL (p190) or a vector control were retro-virally transduced with 
SOCS1 or a GFP control. These mixed populations of transduced (green) and un-
transduced (no green) cells were either cultured in the presence or absence of IL-3. 
GFP expression was followed at regular intervals by FACS. Surprisingly, over-
expression of SOCS1 had no effect on growth of BCR/ABL expressing cells and 
SOCS1 transduced BCR/ABL cells grew at the rates similar to GFP transduced 
cells, as the proportion of SOCS1 transduced GFP positive cells remained constant 
over time (Figure 25A).  In contrast, over expression of SOCS1 severely inhibited 
IL-3 mediated growth of control Ba/F3 cells and resulted in a drastic reduction of 
SOCS1 positive cells, suggesting a selective inhibitory effect of SOCS1 on IL-3 but 
not on BCR/ABL mediated growth of Ba/F3 cells (Figure 25A and 25B). Similar to 
earlier reports using FDCP cells (Bourette et al., 2001), SOCS1 transduced Ba/F3 
cells underwent rapid apoptosis in the presence of IL-3.     Results 
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Figure 25: SOCS1 inhibits IL-3 but not BCR/ABL mediated proliferation. (A) SOCS1 does not 
inhibit growth of BCR/ABL  expressing cells. Ba/F3-FLT3-ITD cells were retrovirally transduced 
SOCS1 and empty GFP vector (control). Mixed populations of transduced and un-transduced cells 
were washed three times with PBS and were further grown in the presence or absence of IL-3 and 
the fate of transduced cells were monitored by measuring the proportion of GFP positive cells every 
day by flow cytometry.  
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5  Discussion 
Aberrant activation of oncogenic RTKs and deregulation of downstream JAK-STAT 
signaling cascades have been described for almost all hematological malignancies 
studied to date. Particularly, constitutive activation of STAT3 and STAT5 are 
frequently found in leukemia (Benekli et al., 2003; Garcia and Jove, 1998). FLT3-
ITD, a frequent activating mutation in AML also activates STAT5 and induces its 
target genes like PIM kinases and SOCS genes (Mizuki et al., 2003).  
Hematopoietic cytokines regulate steady state production of blood cells and their 
proper function. Physiological responses of cytokines mediated majorly by JAK-
STAT pathway. Interestingly cytokines and oncogenes share several components 
of JAK-STAT pathway. Of which, important are SOCS genes, physiological 
negative regulators of cytokines were induced by oncogenes raising important 
question whether they are mediating immune escape of transformed cells. It 
remained unclear how transformed cells escape the tight regulatory cytokine 
networks that normally control the cell cycle, survival and lineage choice of 
hematopoietic stem and progenitor cells (Rieger et al., 2009). 
Here we showed that SOCS genes, mainly SOCS1, a tumor suppressor gene was 
highly induced by FLT3-ITD.  Expression of SOCS1 with FLT3-ITD inhibited 
external cytokine signals and aggravated FLT3-ITD mediated myeloproliferative 
disease with a reduced latency. This work suggests that SOCS proteins (SOCS1 as 
an example) are being part of escape mechanism from cytokine control in FLT3-
ITD mediated leukemogenesis. In vitro data also suggests a similar mechanism is 
true in the context BCR/ABL, an activated kinase similar to FLT3-ITD. 
FLT3-ITD induces SOCS1 expression 
Numerous biological differences between FLT3-ITD and FL-stimulated FLT3-WT 
have been described to date, including the striking ability of FLT3-ITD to cause 
colony growth in semi-solid methylcellulose  –  as an in vitro  surrogate for 
transformation  –  while FL-stimulated FLT3-WT does not (Brandts et al., 2007; 
Hayakawa et al., 2000; Kiyoi et al., 2002; Mizuki et al., 2000; Mizuki et al., 2003; 
Rocnik et al., 2006; Stirewalt and Radich, 2003)  Importantly, FLT3-ITD (but not 
ligand-activated FLT3-WT) activates STAT5 and induces expression of its target 
genes (Mizuki et al., 2003). ). Also, constitutive STAT5 has been reported in about     Discussion 
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70% of AML blasts (Birkenkamp et al., 2001). By analyzing global 
phosphoproteomic changes induced by FLT3-ITD, we have recently found that 
mislocalization of FLT3-ITD to the endoplasmic analysis causes aberrant STAT5 
activation  (Choudhary et al., 2009). We have now performed a systematic 
expression analysis of the STAT5 target genes CIS, SOCS1, SOCS2 and SOCS3 
(Figures 8-11). These experiments consistently demonstrated elevated CIS and 
SOCS1 expression in human FLT3-ITD positive AML cell lines in a kinase-
dependent manner (Figure 10 A and B), in murine lymphoid and myeloid cell lines 
overexpressing FLT3-ITD (Figure 8 A and B) and in retrovirally transduced primary 
murine bone marrow (Figure 9). This was also the case for SOCS2 and SOCS3 in 
most experiments. Importantly, the analysis of human AML samples has revealed a 
significant increase of SOCS1 (but not SOCS3) expression in samples with FLT3-
ITD expression compared to FLT3-WT
+  AML samples (Figure 11 A and B). 
Importantly, decreased SOCS1 protein expression was also shown upon FLT3-ITD 
kinase inhibition (Figure 10C). These data demonstrate a consistent pattern of 
increased SOCS1 expression in the presence of FLT3-ITD, and –  to a lesser 
degree – of other SOCS family members. Similar observations were made in TEL-
Jak2 (Monni et al., 2001) and v-Abl overexpressing cell lines (Limnander et al., 
2004). 
SOCS1 does not affect FLT3-ITD mediated transformation or signaling but 
abolished cytokine signaling 
We have previously shown that FLT3-ITD phosphorylates STAT5  directly, 
independently of Jak kinase family members (Choudhary et al., 2007). We 
therefore analyzed the biological effects of SOCS1 overexpression in the presence 
or absence of FLT3-ITD by use of a T2A constructs which allows for expression of 
both SOCS1 and FLT3-ITD in the same target cell (Szymczak et al., 2004). In the 
32D cell line model, SOCS1 overexpression protected FLT3-ITD from the 
antiproliferative effects of INFα  and IFNγ  (Figure 13A) and abrogated the IFN-
mediated STAT1 phosphorylation (Figure 14), as SOCS1 is known to inhibit STAT1 
activation downstream of IFNα, IFNβ and IFNγ (Alexander et al., 1999; Fenner et 
al., 2006). Also, IFNα- and IFNγ-induced STAT1 activation was diminished in 32D 
cells expressing FLT3-ITD alone, presumably due to low level expression of 
endogenous SOCS1 (Figure 14).     Discussion 
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As previously shown (Choudhary et al., 2007), FLT3-ITD was resistant to SOCS1 
overexpression, while expression of SOCS1 alone causes a rapid loss of cells that 
cannot be rescued by IL3-treatment (Figure 13 B and C). Also, in the absence of 
FLT3-ITD, we could not obtain 32D cells stably expressing SOCS1 (data not 
shown), consistent with similar observation made in the IL-3 dependent, myeloid 
cell line FDC-P1  (Bourette et al., 2001). In agreement with these findings, co-
expression of SOCS1 with FLT3-ITD did not alter constitutively activated signaling 
pathways when compared to FLT3-ITD alone, as measured by p-AKT, p-ERK and 
p-STAT5 levels (Figure 12).  
In order to address the role of SOCS1 in a more physiological setting, further 
experiments were performed in primary murine hematopoietic stem and progenitor 
cells (Figures 15-20). As seen by others for M-CSF (Bourette et al., 2001) and G-
CSF (van de Geijn et al, 2004), overexpression of SOCS1 led to smaller (data not 
shown) and fewer colonies under pro-proliferative conditions with IL3, IL6 and SCF, 
when compared to controls (Figure 15C). In the presence of FLT3-ITD, however, 
co-expression of SOCS1 did not affect colony growth under these conditions 
(Figure 15C, left part). Importantly, under the conditions with IFNγ, co-expression of 
SOCS1 with FLT3-ITD led to significantly more colonies when compared to FLT3-
ITD alone (Figure 15C, right part). Due to the fact that FLT3-ITD induces SOCS1 
expression (Figure 15A and B), colony formation was observed in the presence of 
IFNγ,  however  when  SOCS1  is  overexpressed  (SOCS1-T2A-FLT3-ITD) colony 
formation is further enhanced in a dose-dependent manner (Figure 15C). As 
SOCS1 has been shown to be the major inhibitor of IFNγ signaling (Alexander et al, 
Cell 1999), this data suggests that co-expression of (either endogenous or 
exogenous) SOCS1 protects FLT3-ITD from the anti-proliferative and possibly 
deleterious effects of IFNγ. These findings contrast to previous reports which have 
demonstrated that SOCS1 can inhibit transformation by TEL-JAK2 and by 
oncogenic VAV through their ubiquitination and proteosomal degradation (Frantsve 
2001, Rottappel 2002, De Sepulveda 2000), suggesting that SOCS1 can act as a 
substrate-specific recognition component of the E3 ubiquitin ligase complex 
(Kamizono et al JBC, 2001).  
It had previously been shown that FLT3-ITD overexpression in primary bone 
marrow does not increase replating efficiency.(Lee et al., 2007) We postulated that     Discussion 
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the cytokine escape mechanism in SOCS1-overexpressing cells may contribute to 
self-renewal of hematopoietic stem cells; however, replating assays showed no 
significant differences between FLT3-ITD alone and SOCS1/FLT3-ITD conditions 
(Figure 15D). 
SOCS1 significantly shortened the latency of FLT3-ITD induced 
myeloproliferative disease in vivo  
We next asked whether co-expression of SOCS1 would affect the transforming 
phenotype of FLT3-ITD in vivo and made again use of our FLT3-ITD and SOCS1-
T2A-FLT3-ITD constructs, which leads to similar FLT3-ITD protein levels 
(Figure15B).  It was previously been shown that in bone marrow transplantation 
models and in knock-in models FLT3-ITD leads to the development of a 
myeloproliferative disease or lymphoid disease.(Grundler et al., 2005; Kelly et al., 
2002b; Lee et al., 2005; Lee et al., 2007)  
As shown in the post-transplantation follow-up, mice transplanted with either FLT3-
ITD or SOCS1-T2A-FLT3-ITD expressing bone marrow revealed significantly 
higher GFP-positive cells and higher WBC counts, with a tendency towards lower 
hemoglobin and platelet levels (Figure 16). In addition, the biological advantage of 
GFP-positive cells appeared the most pronounced in the SOCS1/FLT3-ITD arm. 
On the contrary, as expected, SOCS1-expressing cells rapidly disappeared from 
the peripheral blood, demonstrating a pronounced biological disadvantage (Figure 
16A). The survival data demonstrates a clearly more aggressive phenotype in those 
mice co-expressing both SOCS1 and FLT3-ITD, with a shorter latency in MPD 
development (Figure 20A) and increased liver weight compared to FLT3-ITD alone 
(Figure 18C). Disease was manifested in peripheral blood, spleen, liver and bone 
marrow (Table 2 and 3). The mice in both groups developed either MPD or ALL 
with a 100% penetrance, whereas mice transplanted with SOCS1 transduced cells 
did not develop any disease. Previously, in a similar study, co-expression of 
SOCS1 prolonged the latency of disease by TEL-JAK2 in vivo in a bone marrow 
transplant model. This was mainly attributed to the degradation of TEL-JAK2 and 
inhibition JAK kinase activity leading to diminished ERK activation by exogenously 
expressed SOCS1(Frantsve et al., 2001).  In contrast to this, in our model we 
neither observed degradation of FLT3-ITD nor diminished ERK activation by 
SOCS1 co-expression. Thus, SOCS1 functions in a context-dependent manner.     Discussion 
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This is due to the fact that FLT3-ITD directly activates STAT5 and does not activate 
JAK kinases, which is a prerequisite for SOCS1 mediated degradation. (Choudhary 
et al., 2007)  When we carefully analyzed median survival and phenotypes, 
decreased median survival in SOCS1 co-expressing group was exclusively 
contributed by MPD phenotype but not by ALL phenotype suggesting SOCS might 
play an important role in the myeloid compartment. Taken together our data provide 
a proof of principle that induction of SOCS proteins by FLT3-ITD is a mechanism to 
escape the external cytokine control and ultimately contributing to the development 
of leukemogenesis. We think this may be a general mechanism applicable to many 
other oncogenes that activate the STAT5 pathway and for which JAK kinase activity 
is indispensible for the transformation, such as BCR/ABL and TEL-PDGFβR.  
BCR/ABL induces SOCS expression 
Published results suggest that BCR/ABL mediated STAT5 activation may not need 
Jak2 and that it is mediated majorly by HCK or by direct phosphorylation (Ilaria and 
Van Etten, 1996; Klejman et al., 2002). CIS, SOCS2 and SOCS3, STAT5 target 
genes have been shown to be expressed in BCR/ABL
+ CML patients (Schultheis et 
al., 2002; Takahashi et al., 2003; Tauchi et al., 2001). Similar to previous finding in 
CML patients, here we found increased expression of CIS, SOCS2 and SOCS3 in 
BCR/ABL  positive long-term cultured ALL cells compared to BCR/ABL  negative 
long-term cultured ALL cells (Figure 21). Further in BCR/ABL positive long-term 
cultured ALL cells CIS, SOCS2 and SOCS3 expression is decreased upon imatinib 
treatment (Figure 22). Kinase activity of BCR/ABL is required for CIS, SOCS1 and 
SOCS3 expression in K562, a BCR/ABL  positive leukemic cell line (Figure 23). 
Ectopic expression of BCR/ABL in murine bone marrow stem cells led to increased 
expression of CIS, SOCS1 and SOCS3 genes (Figure 24).  In summary SOCS 
genes (CIS, SOCS1-3) expression is driven by BCR/ABL in primary patient cell 
lines and in murine bone marrow stem cells.  
BCR/ABL mediated transformation resistant to SOCS1 
We hypothesized that, BCR/ABL mediated STAT5 activation is resistant to SOCS 
proteins because it is not dependent on Jak2 and hence SOCS1 may not affect 
BCR/ABL mediated transformation. To test our hypothesis, we transduced Ba/F3 
cells expressing BCR/ABL  with SOCS1 retrovirus. We found that SOCS1 over-    Discussion 
  67 
expression neither inhibited nor reduced BCR/ABL mediated proliferation, showing 
that BCR/ABL  is resistant to SOCS1 mediated growth inhibition (Figure 25A). 
However, as expected, IL-3 mediated proliferation is inhibited by SOCS1 (Figure 
25B). 
Previously, CIS, SOCS1 and SOCS2 expression was shown to reduce but not 
inhibit the transformation potential of BCR/ABL (Rottapel et al., 2002; Schultheis et 
al., 2002; Tauchi et al., 2001). In our experiments we did not observe reduced 
growth of SOCS1 transduced BCR/ABL  cells. In agreement with our results, 
another study found that SOCS1 expression did not affect transformation potential 
of  BCR/ABL  (Frantsve et al., 2001). Our data suggest that the SOCS gene 
expression in BCR/ABL transformed cells may shield cells from cytokine control 
such  as IL-3 (Figure 25B).  To support our hypothesis, CML patients, who 
responded poorly to IFNα, had increased SOCS3 expression. Hence we conclude 
that SOCS gene expression by BCR/ABL may have clinical implications concerning 
cytokine therapy. 
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